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Fragile X Syndrome (FXS) is the most common form of inherited mental retardation 
affecting 1:3600 males and 1:8000 females (Cornish et al., 2008).  The primary cause is a 
silencing of the FMR1 gene, via increased CGG trinucleotide repeats, which encodes for the 
Fragile X Mental Retardation Protein (FMRP) (Santoro et al., 2012).  The current prevailing 
theory for the molecular mechanism mediating FXS molecular, physical, and behavioral 
phenotypes is centered around dysregulation of down-stream products of the metabotropic 
glutamate receptor (mGluR) (mGluR Theory) (Bear et al., 2004).  However recent clinical trials 
using mGluR inhibitors have all failed, attributing to various factors such as a need for optimized 
dosage, developmental time for intervention, better metrics for human studies, and most 
prominently complexity of the mGluR pathway (Scharf et al., 2015).  With this ubiquitous 
failure of mGluR inhibitors, new thrusts have been initiated to determine which of the 
downstream components of the mGluR pathway is leading to and causing FXS phenotypes.   
In the pursuit of isolating and determining potential causes/therapeutic targets for 
intervention, the current dissertation explored the role of vascular endothelial growth factor A 
(VEGF-A), a downstream component of mGluR.  This dissertation will outline a series of studies 
where we demonstrate that VEGF-A is elevated in adult FXS mice and that modulation of this 
elevated VEGF-A can attenuate many FXS abnormalities.  In Chapter 2, we obtain 
developmental expression profiles of the VEGF Family of molecules and their Receptors to help 
understand where this dysregulation occurs and how it manifests throughout development.  Next, 
Chapter 3 we found that through blocking VEGF-A, Synapsin-1 levels (a presynaptic marker) 
were reduced to wildtype (WT) levels and resulted in a rescue of physical and behavioral FXS 
phenotypes (Belagodu et al., 2017).  Chapter 4 explored and characterized ultrasonic 
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vocalization (USV) abnormalities in FXS mice to find more human relevant behavioral metrics 
to assess potential therapeutic interventions (Belagodu et al., 2016).  Utilizing these studies, 
Chapter 5 assessed the extent to which blocking VEGF-A can rescue many FXS behavioral 
abnormalities, such as USV production profiles and behavioral measures of locomotion, anxiety, 
and stereotypy.  Finally, to determine which of the VEGF Receptors are driving the beneficial 
effects of blocking VEGF-A, Chapter 6 utilized VEGF Receptor specific blockers to assess 
similar molecular and behavioral properties examined following blocking of VEGF-A.  Overall 
these studies will help to provide further insight into which of the downstream components of the 
mGluR pathway are playing a role in FXS.  In particular these studies will establish which of the 
VEGF Family and Receptors are driving FXS abnormalities and thus may serve as a viable target 
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CHAPTER 1: INTRODUCTION 
 
Fragile X Syndrome Overview 
 
Fragile X Syndrome (FXS) is the leading form of inherited mental retardation and the 
most common known single gene cause for autism spectrum disorder (ASD).  The syndrome 
affects roughly 1:3600 males and 1:8000 females (Cornish et al., 2008).  FXS is caused by an 
increase in CGG trinucleotide repeats at the 5’ encoding region of FMR1, the gene that codes for 
the Fragile X Mental Retardation Protein (FMRP).  This results in hypermethylation and 
transcriptional silencing of FMR1. Normal individuals have less than 50 CGG trinucleotide 
repeats and thus do not exhibit any deficits in FMRP production.  FXS premutations have 50-200 
CGG trinucleotide repeats, are able to produce low levels of FMRP and have a different 
phenotypic profile than FXS full mutations (Santoro et al., 2012).  For an extensive review of 
FXS premutations see (Loesch and Hagerman, 2012).  FXS full mutations have more than 200 
CGG trinucleotide repeats (McLennan et al., 2011) resulting in hypermethylation,  chromatin 
condensation and transcriptional silencing of FMR1 (Pieretti et al., 1991; Verkerk et al., 1991).  
The remainder of this review will focus on this full mutation referred to as FXS, where no FMRP 
is produced. 
FXS is associated with many physical and behavioral characteristics.  FXS patents have 
been shown to have elongated faces, prominent foreheads, macroorchidism in males, prominent 
ears, soft skin, flat feet, hyperextensible finger joints (McLennan et al., 2011), and hypotonia 
(Goldstein and Reynolds, 1999).  Behavioral phenotypes are more complex.  The most common 
impairments are anxiety, attention deficit hyperactivity disorder, hyperarousal to sensory stimuli, 
obsessive-compulsive disorder (Cordeiro et al., 2011), general autistic-like behavior (Miller et 
al., 1999), heightened food selectivity generally based on texture (Raspa et al., 2010), and trouble 
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sleeping (Kronk et al., 2010).  In addition to these abnormalities, FXS patients exhibit numerous 
molecular and neuronal deficits that many believe are the underlying cause for the behavioral 
and physical characteristics mentioned above.  These molecular and neuronal deficits are 
discussed in more detail below. 
Role of FMRP in FXS 
 
While the lack of FMRP is what drives the FXS phenotype, the cause of the syndrome is 
the increased number of trinucleotide repeats in concert with hypermethylation (Smeets et al., 
1995).  During replication, the trinucleotide repeats cause slipping of the three-way DNA 
junction.  This slip causes activation of repair mechanisms that add more repeats into the gene, 
further increasing the number of CGG trinucleotide repeats (Pearson et al., 2002).  However, this 
expansion of the CGG trinucleotide repeats is not believed to be the sole cause for the 
transcriptional silencing of FMR1, rather the methylation of these CGG trinucleotide repeats 
results in the transcriptional silencing of FMR1 (Sutcliffe et al., 1992).  These findings were later 
supported with the discovery of two patients that had expanded CGG trinucleotide repeats 
without the methylation but normal levels of FMR1 and its protein product FMRP (Smeets et al., 
1995). 
Although FMRP can be found in a variety of tissue in the body, it is most abundant in the 
brain and testes.  Within the brain, FMRP is localized mainly to neurons where it can be found in 
the cell body, dendrites, and dendritic spines (Devys et al., 1993).  FMRP’s believed primary role 
in neurons is to down regulate the translation of target messenger RNAs (mRNA; RNA 
molecules which help communication between DNA and ribosomes) in dendritic spines.  
However, FMRP has multiple alternatively spliced isoforms suggesting various functions for 
each (Ashley et al., 1993; Verkerk et al., 1993; Banerjee et al., 2010).   
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The most prominent FMRP isoform in humans contains three  hnRNP K-protein 
homology domains (KH0, KH1 & KH2) and an arginine-glycine-glycine (RGG) box, totaling 
four RNA binding domains (Siomi et al., 1993; Hu et al., 2015).  Of these  KH domains KH2 has 
been extensively explored, as mutations at this domain results in patients being null for FMRP 
resulting in a rather extreme manifestation of FXS (De Boulle et al., 1993).  This is counter to 
the majority of FXS patients where the root cause for the lack of FMRP is derived by the 
excessive presence of CGG trinucleotide repeats and subsequent methylation of the 5’ region in 
the FMR1 gene (Fu et al., 1991; Oberle et al., 1991; Verkerk et al., 1991; Sutcliffe et al., 1992).  
These KH2 mutation cases, specifically at I304N, have led to additional investigation of the role 
of FMRP in mRNA binding.  This KH2 domain has been suggested to bind to a “kissing 
complex motif” which in turn mediates the interaction between KH2 and various polyribosomes 
found in the brain (Darnell et al., 2005).  In exploring these binding interactions, various 
potential mRNA target structures or sequences for KH2 have been implicated; however, this is a 
growing research direction with many conflicting findings that need further investigation 
(Ascano et al., 2012; Anderson et al., 2016).      
Alternatively, through co-immunoprecipitation various components of the microRNA 
(miRNA) pathway that interact with FMRP via the RGG box have been determined (Edbauer et 
al., 2010).  MicroRNAs are small non-coding RNA molecules that have two known functions: 
RNA silencing and post-transcriptional regulation of gene expression (Ambros, 2004; Bartel, 
2004), driving overall regulation and production of various proteins.  Interestingly, the RGG box 
in FMRP, along with the aforementioned miRNAs, also binds to mRNAs containing G-
quadruplexes (Darnell et al., 2001).  G-quadruplexes are stable secondary structures found on 
both nucleic acids and are heavily involved with regulation of ribosomal scanning.  Through 
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examination of the domains found in FMRP and screening for targets of those components, 
extensive lists of its potential targets have been determined, helping to assess FMRP’s function 
such as shuttling of mRNA between the nucleus and cytoplasm, mediating localized synaptic 
protein synthesis via mRNA modulation (Antar et al., 2005), and inhibition of mRNA translation 
(Laggerbauer et al., 2001).  
In exploration of FMRP as a translation repressor of mRNA targets, it was further found 
to co-sediment with polyribosomes in subcellular fractions, suggesting that mRNA repression is 
a result of FMRP binding to polyribosomes.  Once bound FMRP is believed to have inhibitory 
effects on mRNA translation by blocking the eIF4F complex through enlisting of CYFIP1 
(Napoli et al., 2008), stalling ribosomes during the elongation phase of translation (Stefani et al., 
2004), or by recruiting RNA-induced silencing complex (RISC) (Caudy et al., 2002).  As a 
possible mechanism mediating these different functions, FMRP has been shown to undergo 
various posttranslational modifications.  This allows the protein to slightly change in order to 
fulfill these different roles of binding to various sites or interacting with different molecules.  
FMRP exhibits four main post-translational/post-transcriptional modifications, phosphorylation, 
ubiquitnation, splicing, and methylation.  Phosphorylation of FMRP results in the inhibition of 
translation as it binds to stalled untranslating polyribosomes and RISC, but not with Dicer 
(Zhang et al., 2001; Menon and Mihailescu, 2007; Menon et al., 2008).  Ubiquitnation results in 
increased translation as it causes FMRP to degrade in the synapse, removing its inhibitory affect 
(Westmark and Malter, 2007).  Splicing (the post-transcriptional modification) results in the 
removal of specific exons, altering FMRP localization (Muddashetty et al., 2007).  Finally, 
methylation alters FMRP’s specificity to binding various mRNAs, which can result in the 
regulation of various proteins throughout the body (Westmark and Malter, 2007).   
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Although very complex, these molecular deficits are believed to be the underlying cause 
for FXS dendritic spine abnormalities, resulting in the FXS cognitive and behavioral deficits. 
The most notable dendritic spine abnormality seen in FXS brains when compared to WT counter 
parts is the presence of an excess amount of immature looking long dendritic spines (Irwin et al., 
2001; Galvez and Greenough, 2005; Grossman et al., 2006).  Through developmental analyses 
these dendritic spine abnormalities were proposed to be due to a lack of properly regulated 
developmental dendritic spine elimination (Galvez et al., 2003; Galvez and Greenough, 2005), 
particularly due to elevated formation and elimination rates (Pan et al., 2010).  This was further 
supported in a FXS Drosophila model where dFMRP was overexpressed, resulting in a more 
reduced dendritic spines density, suggesting excessive dendritic spine elimination or reduced 
dendritic spine production (Zhang et al., 2001; Pan et al., 2004).  These studies suggest that the 
absence of FMRP drives the abnormal dendritic spine morphology and that proper FMRP 
expression is required for normal network growth and communication.  
mGluR Theory of Fragile X Syndrome 
 
The prevailing theory for the molecular mechanism mediating FXS abnormalities 
revolves around the hyperactivation of metabotropic glutamate receptors (mGluR) resulting in 
exaggerated protein synthesis downstream of mGluR.  To establish a correlation, an extensive 
review between Group 1 mGluR functionality and behavioral/cognitive tasks was conducted by 
Mark Bear, from which the major points have been summarized in the table below (Bear et al., 






   
Group 1 mGluR Function FXS Manifestation 
mGluR5 in the Amygdala has been found to 
help regulate emotionally salient experiences, 
and helps encode fear and anxiety (Rodrigues 
et al., 2002). 
FXS mice have been observed to have aberrant 
contextual and conditioned fear responses 
(Paradee et al., 1999). 
Many mGluR5 antagonists reduce anxiety 
(Tatarczynska et al., 2001). 
FXS patients have increased anxiety and 
autistic-like behavior (Miller et al., 1999; 
Cordeiro et al., 2011). 
Habit formation via corticostriatal synapses is 
dependent on Group 1 mGluR activation 
(Graybiel, 1998; Gubellini et al., 2003). 
FXS patients have obsessive-compulsive 
disorders (Cordeiro et al., 2011). 
Antagonists to mGluR5 reduce audiogenic 
seizure sensitivity in mice (Chapman et al., 
2000). 
FXS patients and mice have increased 
occurrence and sensitivity to audiogenic 
seizures (Chen and Toth, 2001; Berry-Kravis, 
2002; Incorpora et al., 2002). 
Long-term changes in excitability of 
neocortical layer 5 neurons are mediated by 
mGluR5 activation.  This activation results in 
long-term potentiation of intrinsic excitability 
which in turn reduces afterhyperpolarization 
outward current, allowing the cortical network 
to be more excitable (Sourdet et al., 2003).  
Furthermore, increased skin mGluR5 
activation increases pain sensitivity 
(Neugebauer et al., 1999; Walker et al., 2001; 
Tachibana et al., 2003). 
FXS patients have hyperarousal to sensory 
stimuli and greater sensory evoked potentials 
(Castren et al., 2003; Cordeiro et al., 2011). 
Mice lacking Group 1 mGluRs have reduced 
pre-pulse inhibition response (Brody et al., 
2003). 
FXS mice have enhanced response to pre-pulse 
inhibition (Chen and Toth, 2001; Nielsen et al., 
2002). 
Maintenance of the circadian rhythm has been 
linked to activation of Group 1 mGluRs (Park 
et al., 2003). 
The FXS Drosophila model have altered 
circadian rhythms (Dockendorff et al., 2002; 
Inoue et al., 2002; Morales et al., 2002). 
Table 1.1. Overview of correlations between Group 1 mGluRs and FXS that lead to the 
development of the mGluR theory for FXS. 
 
One of the common neuronal characteristics of FXS is enhanced LTD compared to WT 
counterparts.  The main mechanisms for LTD induction, utilizing NMDA or mGluR receptors, 
have been characterized in various brains regions.  Analyzing these two forms of LTD served as 
the initial basis for extrapolating the core mechanism driving many of the FXS phenotypes.  
NMDA induced LTD has been primarily characterized in the hippocampus and traditionally 
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involves the internalization of AMPA receptors (Carroll et al., 1999).  Another key characteristic 
is that NMDA LTD is entirely independent of protein synthesis during the early stage (Huber et 
al., 2000; Sajikumar and Frey, 2003).  As with NMDA induced LTD, mGluR induced LTD also 
involves the internalization of AMPA receptors (Snyder et al., 2001).  However, mGluR-LTD is 
protein synthesis dependent and is driven by the translation of preexisting mRNA (Huber et al., 
2000).   
This dependence on preexisting mRNAs is of  particular importance as FMRP has been 
shown to bind mRNA targets downstream of mGluR, coupled with the direct correlation between 
mGluR stimulation and FMRP activity, suggesting that proper FMRP expression is critical for 
driving the protein synthesis dependent mGluR-LTD (Bear et al., 2004; Darnell et al., 2011).  
Furthermore, as mentioned before, mRNA targets of FMRP have been found in dendritic spines 
indicating their involvement in the LTD process (Miyashiro et al., 2003; Antar et al., 2005; 
Huang et al., 2005).  Studies have indicated that mGluR is expressed in multiple regions in the 
brain (Oliet et al., 1997; Huber et al., 2001), and along with FMRP being observed in most 
neurons (Devys et al., 1993), suggest that a link between the two could result in the deficits seen 
in FXS, discussed in detail above in Table 1.1. 
Validation of the mGluR Theory of FXS as a Treatment Paradigm 
 
In support of the mGluR theory offering a likely site for therapeutic intervention many 
FXS animal studies provided promising results.  FXS Drosophila that lacked mGluR displayed a 
correction of glutamate receptor trafficking, synaptic plasticity, presynaptic ultrastructure, and 
motor behavior (Pan and Broadie, 2007; Pan et al., 2008; Repicky and Broadie, 2009).  
Likewise, FXS mice that were heterozygote for the Grm5 gene, thus only expressing 50% of the 
normal mGluR5 levels, exhibited decreased sensitivity to audiogenic seizures; reduction in the 
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presence of immature dendritic spines; increased and heighted response in evoked potentials to 
contralateral eye depression and ipsilateral eye potentiation following monocular deprivation; 
reduction in hippocampal protein synthesis; reduction of excessive LTD; and restoration of 
normal extinction in inhibitory avoidance behavior (Dolen et al., 2007).  This drastic reversal of 
numerous FXS phenotypes was extremely promising, and suggested that modulating mGluR 
levels can help alleviate FXS abnormalities.   As a result of the promising genetic studies, 
mGluR inhibitors and their efficacies in treating FXS were further explored. 2-methyl-6-
(phenylethynyl)-pyridine (MPEP) was initially taken into consideration as it is an allosteric 
modulator of mGluR5 (the primary Group 1 mGluR receptor that has been suggested to be the 
key player in the FXS mGluR theory).  MPEP can also readily cross the blood brain barrier, 
making it a viable tool for therapeutic interventions (Gasparini et al., 1999).  In FXS Drosophila 
MPEP was found to decrease excitotoxicity induced embryonic lethality (Chang et al., 2008) and 
rescue olfactory and courtship-related memory (McBride et al., 2005; Bolduc et al., 2008).  In 
the FXS zebrafish model embryos generated in an MPEP enriched medium exhibited rescued 
neurite morphology and normal craniofacial development (Tucker et al., 2006).  In the FXS 
mouse model MPEP showed a rescue in open field anxiety; reduced audiogenic seizure 
occurrence rates (Yan et al., 2005); and a rescue in prepulse inhibition deficits (de Vrij et al., 
2008).  Additional studies found that MPEP also corrected epileptiform discharges; decreased 
hippocampal protein synthesis levels to that observed in controls (Chuang et al., 2005; Osterweil 
et al., 2010); decreased hippocampal dendritic filopodia density; rescued mRNA granule 
expression (Aschrafi et al., 2005); and activity of glycogen synthase kinase-3 (Min et al., 2009).  
With successes in reversing multiple FXS phenotypes across species, mGluR inhibitors were 




Recent Clinical Trials to Establish a Reliable Treatment Scheme 
 
Based on the aforementioned studies, the mGluR theory of FXS, and various phenotypic 
rescues of MPEP (mGluR5 antagonist), various clinical trials were pursued utilizing mGluR 
antagonists.  Three main antagonists, developed by different pharmaceutical companies, were 
elected for and pursued, with a fourth that never completed its clinical trial.  These consisted of 
Fenobam developed by McNeil Laboratories, RO4917523/RG7090 (Basimglurant) developed by 
Roche, AFQ056 (Mavoglurant) developed by Novartis, and finally STX107 developed by 
Seaside Therapeutics (this clinical trial was halted until further notice).   
One of the first mGluR clinical trials conducted (NCT01806415) utilized Fenobam.  
Fenobam is a nonbenzodiazepine anxiolytic compound that selectively inhibits mGluR5 via 
negative allosteric modulation (Porter et al., 2005).  In NCT01806415, a single dose of Fenobam 
(50 – 150 mg once a day) was administered to patients ranging from 18 – 35 years of age.  A 
total of 12 males and females were tested with the following endpoints: eye blink inhibition and 
the Carolina Fragile X Project Continuous Performance Test (Scharf et al., 2015).  The Carolina 
Fragile X Project Continuous Performance Test is a modified version of the Continuous 
Performance Test (CPT) optimized for FXS, in which the assessment is shorter with a greater 
focus on auditory/visual attention and impulsivity (Berry-Kravis et al., 2008).  NCT01806415 
failed to show any real significance on both measures (Berry-Kravis et al., 2009; Scharf et al., 
2015). 
Basimglurant, another negative allosteric modulator of mGluR5 developed by Roche, had 
many advantages over Fenobam.  It has a longer half-life and can more easily cross the blood 
brain barrier resulting in improved bioavailability (Lindemann et al., 2015).  Currently, there 
have been three clinical trials utilizing basimglurant; NCT01015430, NCT01517698, and 
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NCT01750957.  The first study, NCT01015430 was conducted to assess safety and tolerability 
levels over a range of dosages (0.1, 0.5, 1.0, & 1.5 mg once a day).  A total of 40 male and 
female FXS patients ranging from 18 – 50 years of age were utilized in this double blind parallel 
study.  Positive results in safety and tolerance levels from this study (primarily for 0.5 and 1.5 
mg doses) then prompted the subsequent two basimglurant studies.  These were both proof of 
concept studies with one focusing on adolescence (NCT01750957) and the other predominately 
in adulthood with some adolescent subjects (NCT01517698).  The first of these two studies, 
NCT01517698, was conducted on 185 males and females ranging from 14 – 50 years of age.  
These subjects received one of two dosages (0.5 or 1.5 mg once a day).  In this double blind 
parallel study, both efficacy and viable biomarkers for assessing the drug were pursued.  Along 
with these, a variety of cognitive and behavioral tasks were also assessed, ranging from Anxiety, 
Depression, Mood Scale, Social Responsive Scale, Clinical Global Impression Rating Scale for 
both Improvement and Severity, and the Aberrant Behavior Checklist Community Scale.  
Unfortunately, this study yielded less than ideal results, with no real benefit resulting from 
basimglurant treatment.  In a second attempt, NCT0170957 was designed in a similar fashion 
with 47 FXS patients ranging from 5 – 13 years of age.  This was the first study to explore the 
effects in a young age group and thus also assessed the safety and tolerance levels of 
basimglurant in children.  As with the aforementioned clinical trial, various cognitive and 
behavioral tasks were assessed: Anxiety, Depression, Mood Scale, Clinical Global Impression 
Rating Scale for both Improvement and Severity, General Behavior Assessment Scale, Aberrant 
Behavior Checklist Community Scale, Repeatable Battery for the Assessment of 
Neuropsychological Status, and the Visual Analog Scale.  Although this study has been 
completed, no formal results have been made public (Scharf et al., 2015).  However, through 
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press reports from Roche, the results were not promising, and the pursuit of basimglurant as a 
form of treating FXS has been halted. 
Mavoglurant, the mGlur5 inhibitor developed by Novartis, was the most extensive 
clinically studied inhibitor, ranging over 5 different clinical trials.  The first study, 
NCT00718341, utilized 30 male and female FXS patients ranging from 18 – 35 years of age in a 
double blind crossover design in which a bi-daily titrated dose (max at 150 mg) was 
administered.  This study was assessing for efficacy and a viable biomarker as a metric of 
success.  A myriad of cognitive assessments (including the Aberrant Behavior Checklist 
Community Scale, Clinical Global Impression Rating Scale for both Improvement and Severity, 
Repetitive Behaviors Scale (Revised), Social Responsiveness Scale, Visual Analog Scale, and 
the Vineland Adaptive Behavior Scale) were also conducted to determine the effectiveness of 
mavoglurant.  Through this trial, tolerance for mavoglurant was found to be acceptable, 
manifesting mainly as mild fatigue or headaches; unfortunately, none of the cognitive 
assessments provided significant beneficial results.  Interestingly, upon further post-hoc 
analyses, it was determined that patients with a fully methylated FMR1 gene had significant 
improvements on the cognitive tests (Jacquemont et al., 2011).  Based on these promising 
findings the next four trials commenced.   
The four subsequent mavoglurant trials were both proof-of-concept trials for both FXS 
adults ranging from 18 – 46 years of age (NCT01253629 & NCT01348087) and FXS 
adolescence ranging from 12 – 18 years of age (NCT01357239 & NCT01433354).  Both studies 
were double-blind parallel studies utilizing both males and females.  A dose response regime was 
tested with bi-daily 25, 50, or 100 mg doses in the first half (NCT01253629; n=175 for adults & 
NCT01357239l n=139 for adolescents) in which efficacy, viable biomarkers, and only the 
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Adaptive Behavior Scale was assessed.  The second half of both studies (NCT01348087; n=148 
for adults & NCT01433354; n=103 for adolescents) were open label, with bi-daily doses 
optimized up to 100 mg.  These studies conducted the same cognitive assessments as in the first 
half with the addition of the Clinical Global Impression Rating Scale and the Repetitive 
Behaviors Scale.  The adolescent study also assessed the Social Responsive Scale.  Despite being 
the largest and most extensive clinical trials, and having promising preliminary data with 
minimal side effects, the trials found no significant improvement in FXS patients (Scharf et al., 
2015).  
 The negative results from the aforementioned clinical trials were less than promising for 
the FXS field, and put into question the prevailing mGluR theory for FXS.  Various explanations 
have been put forth for the rationale between the overwhelming cross species success in 
preclinical trials to the negative results in clinical trials.  One possible explanation for these 
results is in the need to assess an optimal dosage time frame.  This is of particular importance, as 
FXS is a developmental disorder, and thus the timing of the intervention can be critical.  Other 
explanations have focused on a need for better metrics in human clinical trials.  Many of the end 
points utilized in these trials were measured and reported by patient caretakers, and thus were 
variable and subjective.  Finally, other explanations have focused on possible compensatory 
mechanisms masking the effects of inhibiting mGluR I pathways.  Furthermore, the mGluR 
pathway is critically involved in numerous molecular pathways in the body, and thus a global 
inhibition may not be ideal.  This has led to many investigators to explore the 
modulation/regulation of various mGluR downstream components, in hopes of finding a new 





Breakdown of the mGluR Pathway and New Targeted Treatments 
 
mGluRs are a family of receptors that are involved with functions of the central and 
peripheral nervous system.  Ubiquitously found in both central and peripheral nervous systems, 
these receptors function ranges from driving aspects of learning and memory, anxiety, and 
sensory stimuli as well as downstream aspects of protein regulation (Chu and Hablitz, 2000; 
Ohashi et al., 2002). 
 
 
Figure 1.1. Detailed breakdown of the mGluR pathway with therapeutic interventions.  Legend 
denotes the types of molecules found in the pathway.  Red blocks are therapeutic interventions, 
while blue and green blocks are parts of the mGluR pathway.  Of particular note, the green 
blocks indicate the particular downstream pathway of mGluR that results in VEGF production 
discussed in more detail below. 
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Table 1.2. Overview of current therapeutics targeting downstream components of the mGluR 
pathway, and their beneficial effects on FXS. 
 
Therapeutic Target Beneficial Effect 
Rolipram Inhibit PDE4 
Restores enhanced mGluR LTD to WT levels 
in FXS mice, memory impairment and 
structural brain deficits in Drosophila model 
of FXS (Choi et al., 2015). 
Bryostatin-1 Enhance PKC Activation 
Enhanced PSD-95 expression, rescues PKC 
and GSK3β to negatively modulate mGluR 
activity and increases maturation of dendritic 
spines in FXS mice (Sun et al., 2014). 
TGX-221 Inhibit PI3K 
Through inhibition of p110β subunit of PI3K, 
overall protein synthesis in FXS mice derived 
synaptoneurosomes and patient cells were 
reduced suggesting regulation of downstream 
protein synthesis (Gross and Bassell, 2012).  
Metformin Enhance AMPK 
Rescued courtship and olfactory memory in 
FXS Drosophila model (Monyak et al., 2016). 
LiCl 
Inhibit IMPase, IPPase, & 
GSK3β 
Reduction in overall protein synthesis rates in 
FXS mice, with a marked decrease in 
phosphorylation of Akt (Liu et al., 2012). 
Reduces overall GSK3β activity and reduced 
anxiety behaviors (Mines et al., 2010).  
Reduced hyperactivity, rescued excessive 
immature spine morphology, reduced anxiety 
and normalized impaired social interaction 
(Liu et al., 2011). 
Rapamycin Inhibit mTOR 
Reduced intensity of audiogenic seizures 
(Osterweil et al., 2010). 
AR-A014418 Inhibit GSK3β 
Reduced inductance rate of audiogenic 
seizures (Min et al., 2009). 
SB216763 Inhibit GSK3β 
Decreased length of dendritic spines and 
increased hippocampal neurogenesis (Guo et 
al., 2012).  Reduced inductance rate of 
audiogenic seizures and anxiety like behaviors 
observed via open field assessment (Min et 
al., 2009).  Improved ability to learn trace fear 
conditioning and overall spatial memory 
observed via radial arm maze (Guo et al., 
2012). 
Nutlin-3 Inhibit MDM2 
Reduces neuronal stem cell activation and 
restores adult neurogenesis in FXS mice.  
Also rescued performance in novel object 
recognition and location tests (Li et al., 2016). 
PF-4708671 Inhibit S6K1 Reduced overall protein synthesis rates in 
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FXS fibroblasts (Kumari et al., 2014).  
Reduced overall protein synthesis levels, 
increased performance on novel mouse and 
object vs mouse behavior, as well increased 
performance in choice reversal tasks. 
Furthermore, rescued the increased immature 
spine morphology, and macroorchidism 
(Bhattacharya et al., 2016). 
FS-115 Inhibit S6K1 
Reduced overall protein synthesis levels, 
increased performance on novel mouse and 
object vs mouse behavior, as well increased 
performance in choice reversal tasks, and 
reduced marble burying activity. Furthermore, 
rescued the increased immature spine 
morphology, and macroorchidism 
(Bhattacharya et al., 2016). 
Cercosporamide Inhibit eIF4E 
Through reduction of eIF4E phosphorylation 
increased social behavior, reduced levels of 
mGluR induced LTD, hyperactivity, and 
audiogenic seizure induction rates (Gkogkas 
et al., 2014).  
Minocycline Inhibit MMP9 
Increases maturation of dendritic spines in 
hippocampal cell culture (Bilousova et al., 
2009).  Treatment reduced anxiety in elevated 
plus maze and hyperactivity.  Treatment also 
increased exploration in Y maze and 
vocalization rates in FXS mice (Bilousova et 
al., 2009; Rotschafer et al., 2012; Dansie et 
al., 2013).  Improved overall cognition, 
language, anxiety, and mood in FXS patients 
as well as reduced irritability (Paribello et al., 
2010; Utari et al., 2010; Leigh et al., 2013).   
Table 1.2 (cont.). Overview of current therapeutics targeting downstream components of the 
mGluR pathway, and their beneficial effects on FXS. 
 
VEGF Family Molecules and Receptors Overview 
 
To continue to discern the effects of the downstream components of mGluR, and their 
effect on FXS, our lab has been exploring the role of Vascular Endothelial Growth Factor 
(VEGF) in mediating FXS abnormalities.  VEGF is one of the most prominent regulators of 
vascular growth with increased expression being synonymous with increased blood vessel 
growth (Neufeld et al., 1999).  It is critical for proper vascular growth and development, as 
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genetic knockouts are embryonic lethal (Carmeliet et al., 1996; Ferrara et al., 1996).  VEGF is a 
family of proteins that consist of five main proteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D and 
placental growth factor (PLGF). Of these five VEGF proteins, VEGF-A is the most studied and 
the largest driver of angiogenesis (Neufeld et al., 1999; Ferrara et al., 2003).  VEGF-B and 
VEGF-C are known as VEGF related proteins while VEGF-D is also known as c-Fos-induced 
growth factor (Joukov et al., 1996; Lee et al., 1996).  VEGF-B is heavily associated with cell 
adhesion, migration, and regulation (Olofsson et al., 1998).  Although VEGF-C and VEGF-D are 
not as well understood, they are known to have implications towards regulating lymphatic 
angiogenesis (Olofsson et al., 1996; Baldwin et al., 2001; Karkkainen et al., 2002).  Finally 
PLGF has been shown to affect angiogenesis, inflammation, would healing, and plasma 
extravasation (Carmeliet et al., 2001).  These five VEGF proteins are known to interact with one 
of three primary VEGF receptors: VEGFR1, VEGFR2, VEGFR3 (Fig. 1.2). 
 
 
Figure 1.2. Schematic of binding affinities of VEGF Family of molecules to the various VEGF 
Receptors. 
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VEGFR1 (Flt-1) is activated by VEGF-A (de Vries et al., 1992), VEGF-B (Olofsson et 
al., 1998), and PLGF (Park et al., 1994).  The loss of VEGFR1 results in abnormal vascular 
development manifesting through excessive hemangioblast proliferation and a reduction in 
vascular organization (Fong et al., 1995).  VEGFR1 receptor activation can also have 
pronocicpetive effects through activation of kinases which sensitize reactions to heat, pressure, 
and various chemicals, but only when stimulated via VEGF-A (Selvaraj et al., 2015).  
Interestingly, of the 3 family members that target VEGFR1, only VEGF-A targets other VEGF 
receptors with VEGF-B and PLGF only targeting VEGFR1 (Park et al., 1994).  VEGF-A’s other 
and primary target is VEGFR2 (Flk-1) which is the primary driver of angiogenesis and 
microvascular permeability (Dvorak, 2002) as well as being heavily involved with various 
aspects of endothelial cells such as proliferation and survival (Millauer et al., 1993; Zeng et al., 
2001).  VEGFR2 is the more versatile of the VEGF receptors, as it also maintains a weak affinity 
for VEGF-C and VEGF-D (Joukov et al., 1996; Achen et al., 1998).  However there is now 
growing literature suggesting that VEGFR2 (primarily through VEGF-A stimulation) is heavily 
involved with neuronal properties such as increased axonal and neurite outgrowth (Silverman et 
al., 1999; Sondell et al., 1999; Sondell et al., 2000; Jin et al., 2002).  Finally, VEGFR3 (Flt-4) 
has a high affinity for VEGF-C (Joukov et al., 1996) as well as VEGF-D (Achen et al., 1998).  
As suggested from previously mentioned studies focusing on VEGF-C and VEGF-D, VEGFR3’s 
primary role is lymphangiogenesis, but also plays a role in development of and maintaining the 
plasticity of vascular networks during embryogenesis (Kukk et al., 1996; Paavonen et al., 2000; 
Alitalo and Carmeliet, 2002; Laakkonen et al., 2007).  Its role in development has been observed 





Non-vascular Properties of VEGF-A 
 
VEGF-A is primarily produced by endothelial cells, vascular smooth muscle cells, and 
neurons (Barleon et al., 1997; Chua et al., 1998; Schiera et al., 2007).  VEGF-A acts through 
VEGFR1, with minor pronocicpetive effects through activation of kinases which sensitize 
reactions to heat, pressure, and various chemicals (Selvaraj et al., 2015) and vascular 
reorganization (Fong et al., 1995), but primarily through VEGFR2, which as previously stated is 
the primary driver of angiogenesis (Dvorak, 2002).   VEGFR2 can be found on neurons and 
endothelial cells and can result in a variety of functions, particularly increasing neurite 
outgrowth, mitogenesis, angiogenesis, and blood brain barrier permeability-enhancing effects 
(Ferrara et al., 2003; Jin et al., 2006).    
Of particular interest is VEGF-A’s ability to interact directly with various neuronal cells.  
VEGF-A application has been observed to have a neurotropic effect via VEGFR2 in the 
peripheral nervous system manifesting through stimulation of Schwann cell proliferation 
(Sondell et al., 1999).  Additionally, in the central nervous system, VEGFR2 stimulation yields 
axonal growth, and enhancing overall cell survival (Sondell et al., 2000).  Furthermore, VEGF-A 
application stimulates cell proliferation in hippocampal in vitro cultures as well as neurogenesis 
in the dentate gyrus of the hippocampus in vivo (Jin et al., 2002).  VEGFR2 has been found 
directly on axonal growth cones, and with VEGF-A stimulation, has been shown to increase 
overall axonal growth (Sondell et al., 1999).  Finally, direct application of VEGF-A has been 
shown to promote overall neurite outgrowth and overall increased neurite branching (Jin et al., 
2006).  Interestingly, VEGF-A and its interaction with VEGFR2 has been recently implicated in 
learning and memory.  Application of VEGF-A, in concert with NMDA, triggered remodeling of 
the post synaptic density (PSD), resulting in an overall increase in size of the PSD.  This 
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suggested and was confirmed via fluorescent colabeling that VEGFR2 are also localized on 
dendritic spines.  When these dendritic spine VEGFR2s were genetically silenced, eliminating 
the ability of VEGF-A to bind and influence these neurons, an impairment in consolidation of 
fear-related memory was observed (De Rossi et al., 2016).  Interestingly, these non-vascular 
properties of VEGF-A mirror abnormalities seen in FXS and will be discussed in more detail in 
the following section. 
VEGF and Fragile X Syndrome 
 
FXS molecular studies exploring abnormalities in the group 1 mGluR pathway have 
suggested that VEGF would exhibit elevated expression.  As discussed above, group 1 mGluRs 
in FXS is over active (Bear et al., 2004) resulting in excessive activation of its downstream 
processes. In support of this, mTOR (an mGluR1 downstream protein (Hou and Klann, 2004)) is 
over phosphorylated in FXS mice (Sharma et al., 2010).  mTOR is a positive regulator of VEGF 
expression, with increased mTOR activation resulting in increased VEGF expression (Brugarolas 
et al., 2003).  Thus in FXS, increased mTOR activation suggests increased VEGF production. 
Interestingly, increasing VEGF expression can cause many abnormalities consistent with 
those observed in FXS.  Increasing VEGF production would increase blood vasculature, 
subsequently increasing blood flow to brain regions.  Likewise, FXS patient have been reported 
to exhibit abnormal brain blood flow to many brain regions (Kabakus et al., 2006).  Furthermore, 
FXS mice have been shown to exhibit elevated blood vessel density in both primary visual 
cortex and hippocampus (the only two regions examined) (Galvan and Galvez, 2012).   As 
previously mentioned, VEGF-A application has stimulatory and protective capabilities, which 
can be observed in FXS.  FXS have increased Sertoli cell proliferation and neurogenesis in the 
dentate gyrus (Hagerman and Hagerman, 2003; Luo et al., 2010).  VEGFR2 has been observed 
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on axonal growth cones, and with stimulation of VEGF-A results in axonal growth (Sondell et 
al., 1999), mirrored in in the Drosophila model of FXS through excessive axonal growth (Pan et 
al., 2004).  Furthermore application of VEGF-A results in excessive neurite outgrowth (Jin et al., 
2006) consistent with the immature dendritic spine morphology observed in FXS (Galvez et al., 
2003; Galvez and Greenough, 2005).  This hallmark phenotype of increased immature dendritic 
spine numbers is suggested to be due to excessive dendritic spine proliferation (Pan et al., 2010).  
Thus this dendritic spine abnormality, coupled with increased vascularization and blood flow 
could result in over active regions, resulting in the cognitive and behavioral deficits observed in 
FXS (Miller et al., 1999; Kronk et al., 2010; Raspa et al., 2010; Cordeiro et al., 2011; Galvan and 
Galvez, 2012).   
This correlation between excessive VEGF-A and FXS phenotypes suggests that some of 
the FXS characteristics could be explained via excessive VEGF production.  As you will see, our 
findings suggest that VEGF-A is excessively produced in FXS due to the dysregulated mGluR 
pathway.  Furthermore, this excessive production can be modulated through therapeutics and 





CHAPTER 2: CHARACTERIZING NEOCORTICAL DEVELOPMENTAL PROFILES 
OF VEGF FAMILY MOLECULES, RECEPTORS, AND VASCULAR PROPERTIES IN 
FRAGILE X MICE 
Abstract 
 
The Fragile X Syndrome (FXS) is the most common single gene cause for Autism 
Spectrum Disorder and the most prevalent form of inherited mental retardation.  We have 
previously demonstrated that adult FXS mice have abnormal Blood Vessel Density (BVD) 
(Galvan and Galvez, 2012) and elevated Vascular Endothelial Growth Factor A expression 
(VEGF-A).  VEGF-A is one of the most prominent regulators of BVD, and its abnormal 
expression is the most likely cause for FXS BVD abnormalities.  Interestingly, we have also 
demonstrated that attenuating elevated VEGF-A expression can ameliorate many non-vascular 
FXS abnormalities (Belagodu et al., 2017).  These studies have suggested that abnormal BVD 
and VEGF-A expression are an underlying cause for some FXS abnormalities.  However, FXS is 
a developmental disorder and VEGF-A expression along with BVD and their potential role in 
mediating FXS abnormalities during development have never been explored.  Furthermore, 
VEGF-A is one protein in a family of proteins (VEGF-A, VEGF-B, VEGF-C, VEGF-D, & 
PLGF) that activate one of three primary receptors (VEGFR1, VEGFR2, & VEGFR3).  
Abnormal expression of any of these proteins could hinder proper neuronal and cognitive 
development in FXS.  The current study demonstrated that FXS mice exhibit abnormal BVD, 
vascular growth factor and growth factor receptor expression at multiple ages over development.  
Interestingly, many of these abnormal developmental expression patterns correlated with known 
FXS age specific neuronal abnormalities.  Expanding upon our prior examination of adult BVD 
and VEGF-A expression, the current study provides additional insight towards potential 
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The Fragile X Syndrome (FXS) is the most common single gene cause for Autism 
Spectrum Disorder and the most prevalent form of inherited mental retardation (1:3600 in males 
and 1:8000 in females) (Cornish et al., 2008).  Patients with FXS have various physical, 
behavioral, and cognitive abnormalities including cluttered speech, hyperactivity, increased 
seizure susceptibility and difficulty with cognitively demanding tasks (Berry-Kravis, 2002; Van 
Borsel et al., 2008; Cordeiro et al., 2011). Although the cause for FXS is well understood, 
transcriptional silencing of FMR1, the gene that codes for the Fragile X Mental Retardation 
Protein (FMRP) (Pieretti et al., 1991; Verkerk et al., 1991; McLennan et al., 2011; Santoro et al., 
2012), the mechanism by which an absence of FMRP causes these abnormalities is unknown.  
Many studies have suggested that these abnormalities are due to a lack of FMRP inhibition of 
mGluR (metabotropic glutamate receptor) down-stream processes. Specifically, many have 
suggested that over activation of the down-stream complex mTORC1 (mammalian target of 
rapamycin complex 1) in FXS results in abnormal expression for various proteins that result in 
FXS abnormalities (Sharma et al., 2010; Hoeffer et al., 2012).  
Our recent studies have demonstrated that one of these proteins, down-stream of 
mTORC1, that exhibits elevated expression in adult FXS brain is VEGF-A (Vascular Endothelial 
Growth Factor A) (Belagodu et al., 2017).  VEGF-A is one of the most prominent regulators of 
brain vascular growth and the most likely explanation for our prior observed increased 
vasculature in adult FXS mice (Galvan and Galvez, 2012).  Interestingly, recent studies have 
demonstrated that in addition to being found on vascular endothelial cells, the prominent VEGF-
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A receptor (VEGFR2) is also found on the postsynaptic density of neurons which when 
genetically removed hinders acquisition for fear conditioning (De Rossi et al., 2016).  These 
studies have suggested that in addition to a prominent role in vascular growth, VEGF-A also 
plays an active role in learning and memory.  VEGF-A stimulation has also been shown to alter 
many neuronal properties that are disrupted in FXS.  For example, increasing VEGF-A induces 
axonal and dendritic growth consistent with the increased dendritic spine and axonal material 
observed in FXS (Sondell et al., 1999; Irwin et al., 2000; Pan et al., 2004; Galvez and 
Greenough, 2005; Antar et al., 2006; Jin et al., 2006).  Furthermore, chronic VEGF-A 
stimulation induces long term depression like conditions (McCloskey et al 2005), a molecular 
form of learning that is elevated in FXS (Huber et al, 2002).  Collectively these studies suggest 
that increased VEGF-A brain expression mediates more than just FXS vascular abnormalities. 
In support of this hypothesis we have recently demonstrated that blocking VEGF-A’s 
ability to bind to its receptor in adult FXS mice attenuates neuronal and cognitive abnormalities.  
Our studies have shown that blocking VEGF-A decreases adult FXS synapse density in the 
neocortex and hippocampus to that observed in control mice.  Furthermore, our subsequent 
behavioral analyses using the learning paradigm novel object recognition demonstrated that 
blocking VEGF-A also ameliorated adult FXS learning deficits, making them indistinguishable 
from controls (Belagodu et al., 2017).  These studies demonstrate that in addition to modulating 
vasculature, increased VEGF-A expression in adult FXS mice mediates many neuronal and 
cognitive abnormalities.  However, FXS is a developmental disorder and many adult 
abnormalities could be a result of, or at least exasperated by abnormal brain development (Till et 
al., 2012; Telias et al., 2013).   
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Interestingly VEGF-A brain expression during development in FXS is not known.  
Furthermore, VEGF-A is only one of 5 VEGF family molecules [VEGF-A; VEGF-B; VEGF-C; 
VEGF-D; and PLGF (placental growth factor)] that activate one of three primary receptors 
(VEGFR1, VEGFR2, and VEGFR3).  In addition, many VEGF receptors can be activated by 
multiple VEGF family molecules.  For example, VEGFR1 can be activated by VEGF-A, VEGF-
B or PLGF; VEGFR2 can be activated by VEGF-A, VEGF-C or VEGF-D; and VEGFR3 can be 
activated by VEGF-C or VEGF-D (Fig. 2.1).   
 
 
Figure 2.1. Schematic of binding affinities of VEGF Family of molecules to their various VEGF 
Receptors. 
 
Abnormal developmental expression for any of these receptors, VEGF family molecules, 
or subsequent blood vessel density could be an underlying cause for FXS abnormalities.  
Unfortunately, their developmental expression in FXS and potential role in subsequent 
abnormalities has never been explored.  To determine their potential for mediating FXS 
developmental abnormalities, the current study set out to characterize neocortical vascular 
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density, vascular growth factor expression, and vascular growth factor receptor expression across 
development in FXS mice. 
Methods & Analysis 
 
All experimental protocols were conducted in accordance with and approved by the 
Illinois Institution of Animal Use and Care Committee at the University of Illinois at Urbana-
Champaign.  All studies and analyses were further conducted with the researcher blinded to 
genotype and animal age to avoid experimenter bias. 
Housing and Care of Animals 
Male C57/B6 FMR1 knockout (FXS) and wildtype (WT) mice at postnatal day (PND) 10, 
20, 35, and 60 were used for each study.  PND 10 has been noted to be the period prior to a 
significant increase in synaptogenesis in many mouse neocortical brain regions (De Felipe et al., 
1997).  PND 20 was chosen as it corresponds to the beginning of a rise in synaptic plasticity for 
many regions in the brain (Greenough and Chang, 1988; White et al., 1997; Hanover et al., 1999; 
Huang et al., 1999; Dahlhaus et al., 2011; Levelt and Hubener, 2012).  PND 35 is representative 
of a mid-adolescent time point, where the period of rapid increased dendritic and synaptic 
plasticity in most brain regions has ended (Vergouwen et al., 1993; Adriani et al., 2004).  Finally, 
PND 60 was chosen as it corresponds to a young adult and is the age when our prior VEGF-A 
and blood vessel analyses were conducted (Galvan and Galvez, 2012; Belagodu et al., 2017).  
Mice were housed in standard laboratory conditions (12 hrs -12 hrs light/dark cycle with food 
and water provided ad libitum). 
Blood Vessel Density 
 
Once mice reached the appropriate aforementioned ages, an overdose of sodium 
pentobarbital (100 mg/kg) was intraperitoneally administered followed by subsequent 
transcardial perfusion with 1x PBS followed by 4% paraformaldehyde.  Brains were then 
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extracted and post-fixed for 24 hrs in 4% paraformaldehyde followed by 30% sucrose at 4º C.  
The brains were then sectioned into 30 µm coronal sections, and stored at -20º C in 
cryoprotectant (30% ethylene glycol & 30% sucrose in PBS) until ready for 
Immunohistochemistry. 
 For staining and visualizing blood vessels, a modified protocol from (Galvan and Galvez, 
2012) was utilized.  After PBS washes, sections were incubated in pepsin (1 mg/ml) at 37⁰ C for 
10 min for antigen-unmasking.  Sections were then incubated for 30 min in 0.6% hydrogen 
peroxide followed by a 1 hr incubation in TBS-X blocking solution (0.1% Triton X, 5% normal 
goat serum in PBS).  Sections were then incubated for 48 hrs at 4⁰ C in anti-Collagen IV 
antibody (1:300 Millipore in TBS-X).  Following the primary antibody incubation, sections were 
incubated in anti-rabbit secondary antibody (1:100 Vector, Burlingame, CA) for 2 hrs followed 
by incubation in avidin-biotin (Vector, Burlingame, CA) for 1 hr at room temperature.  Finally, 
the antigen was visualized through an incubation in a diaminobenzidine (DAB) solution (0.5 
mg/ml DAB, 6.95 mg/ml nickel ammonium sulfate, 0.033 µl/ml 30% hydrogen peroxide).  
Anatomical landmarks were used to locate the neocortical visual cortex (Paxinos, 2008).  Stained 
sections were imaged on an Olympus BX50 microscope with a Zeiss AxioCam ICc1 camera at 
4x magnification with AxioVision ver 4.8.1.  Once imaged, a 400 x 400 µm
2
 area in each 
subdivision of the neocortical visual cortex [V1, V1M (monocular), & V1B (binocular)] was 
analyzed.  The visual cortex was chosen as it correlates with previous FXS studies of blood 
vessel density (Galvan and Galvez, 2012) and dendritic spine abnormalities (Irwin et al., 2001; 
Irwin et al., 2002).  Collagen IV positive staining was examined using the particle analysis tool 
on ImageJ (http://rsbweb.nih.gov/ij/docs/guide/146-30.html) to determine the percent area 
fraction of blood vessels.  To control for any tears or damage in the tissue, the “white space” was 
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calculated through the same particle analysis procedure and taken out of the area percent 
calculation, resulting in a more accurate representation of the total blood vessel density.   
Volumetric Analysis 
 
To calculate the size of the regions being examined over development, evenly spaced 
sections were then nissl stained using a standard 25% cresyl violet staining protocol.  Using 
standard non-biased stereological techniques, the area of V1, V1M, and V1B were calculated with 
AxioVision ver 4.8.1 for each section and then used to determine the volumes of each region for 
each mouse using the following equations:[(section area * section thickness) * distance to next 
section].   
Growth Factor and Receptor Expression 
 
 To determine expression levels of VEGF family molecules (VEGF-A, VEGF-B, VEGF-
C, VEGF-D and PLGF) and their subsequent receptors (VEGFR1, VEGFR2, and VEGFR3), 
dissected cortical hemispheres, including white matter and hippocampus were utilized.  Samples 
were processed as described in (Belagodu et al., 2017) for large gels to allow for comparison 
across developmental ages.  From each developmental time point FXS (n=3) and WT (n=3) 
mouse brains were homogenized and protein concentration estimated via bicinchonic acid assay 
(Thermo Scientific).  Each sample (40 µg of protein) in a 1:1 loading buffer (475 µl Laemmli + 
25 µl βME) ratio were loaded and run on a large 10% electrophoresis gel at 150 V for 1 hr 
followed by 200 V for 4 hrs.  The separated proteins were then transferred to a nitrocellulose 
membrane at 20 V at 100 mA overnight in 4⁰ C.  The resulting protein embedded membranes 
were then blocked with 5% milk in TBS-T (Tris Buffered Saline with 0.05% Tween 20) and 
probed with a primary antibody for the molecules of interest (VEGF-A 1:1000; Santa Cruz, 
VEGF-B 1:1000; Abcam, VEGF-C 1:1000; Abcam, VEGF-D 1:1000; Abcam, PLGF 1:1000; 
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Abcam, VEGF Receptor 1 (Flt-1) 1:1000; Abcam, VEGF Receptor 2 (Flk-1) 1:1000; Santa Cruz, 
or VEGF Receptor 3 (Flt-4) 1:1000; Abcam).  The membrane was then washed and incubated in 
anti-rabbit or anti-mouse secondary antibody (1:1000; Cell Signaling Technology) for 2 hr prior 
to chemiluminescent substrate exposure for 5 min and imaged via a BioRad ChemiDoc Touch 
Gel Imaging System (BioRad).  After imaging, the blots were reprobed for GAPDH (1:1000; 
Santa Cruz) as a loading control.  The relative intensity of the protein of interest was calculated 
by dividing its optical density by that of GAPDH.  The optical densities were determined through 
Image Lab v5.2.1 (BioRad).  
Statistical Analysis 
 
 Comparisons across developmental time points were conducted with a two-way mixed 
model ANOVA on SAS 9.4 (http://www.sas.com) with age and genotype as between subject 
factors and Bonferroni correction for multiple comparisons.  As noted below, some comparisons 
at specific ages across genotype were further explored with a pair-wise t-test on SAS 9.4.   
Results  
 
Examination of the total V1 region (V1T) blood vessel density (BVD) for WT mice 
demonstrated an expected increase in vascular density over development with a sharp reduction 
at PND 35 (Fig. 2.2a; F(3,52)=3.76; p<0.05), a time point that correlates with an end to the rapid 
synaptic plasticity observed at PND 20 (Greenough and Chang, 1988; White et al., 1997; 
Hanover et al., 1999; Huang et al., 1999; Dahlhaus et al., 2011; Levelt and Hubener, 2012).  
Interestingly, this increase with subsequent reduction was not observed in FXS mice.  Rather, in 
FXS mice the overall BVD maintains a general increase throughout development (Fig. 2.2a).  
Further comparisons across age demonstrated that FXS mice had significantly reduced BVD at 
PND 20 and elevated BVD at PND 60 compared to WT mice (Fig. 2.2).  Our findings at PND 60 
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are consistent with our prior Galvan and Galvez (2012) study demonstrating elevated BVD in 
FXS mice. 
Upon obtaining these initial findings V1T was further sub-divided into three regions: V1, 
V1M and V1B.  In V1 and V1M, WT mice exhibited a similar increase in BVD at PND 20 (V1: 
Fig. 2.2b; F(3,48)=3.81; V1M: Fig. 2.2c; F(3,51)=3.96; p<0.05) that was not observed in FXS mice.  
In V1B WT mice also exhibited elevated BVD at PND 20; however, it did not reach statistical 
significance (age*genotype p=0.0561) (Fig. 2.2d).  Interestingly, in V1M, FXS mice exhibited 
significantly elevated BVD at PND 60 (Fig. 2.2c; F(3,51)=3.96; p<0.05) similar to that observed in 
V1T.  These findings are consistent with our prior study examining BVD in FXS mice (Galvan 






Figure 2.2. Fragile X mice (FXS) display a dysregulated growth and development of blood 
vessel density in the visual cortex compared to their wildtype (WT) counterparts.  a. 
Quantification of blood vessel density in total visual cortex (V1T is a sum of V1, V1 Monocular, 
and V1 Binocular) across all developmental time points.  b. Quantification of blood vessel 
density in mouse V1 visual cortex across all developmental time points.  c. Quantification of 
blood vessel density in mouse monocular visual cortex (V1M) across all developmental time 
points.  d. Quantification of blood vessel density in mouse binocular visual cortex (V1B) across 
all developmental time points.  Note: V1B displayed elevated BVD at PND 20, but did not reach 
significance: age*genotype p=0.0561.  *<0.05 
 
To determine which of the major angiogenic factors are driving these changes in blood 
vessel density, Western Blot analyses was performed for each VEGF family molecule at the 
different ages.  An overall ANOVA demonstrated a significant age*geno differences for VEGF-
A (Fig. 2.3a; F(3,16)=11.91; p<0.05), VEGF-B (Fig. 2.3b; F(3,16)=21.11; p<0.05), and PLGF (Fig. 
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2.3e; F(2,12)=4.81; p<0.05).  Individual pair-wise comparisons will now be discussed at each age 
to further elucidate specific FXS developmental abnormalities. 
At PND 10, the period prior to increased synaptogenesis in the neocortex (De Felipe et 
al., 1997), no differences were seen in VEGF-A or VEGF-C; however, a pair-wise t-test revealed 
that VEGF-D was significantly reduced in FXS mice (t(4)=-2.82; p<0.05) (Fig. 2.3d).  
Interestingly, FXS mice also exhibited elevated expression of VEGF-B (Fig. 2.3b; F(3,16)=21.11; 
p<0.05) and there was no expression of PLGF in either genotype.       
The expression profiles at PND 20, the period that marks the peak of dendritic and 
synaptic plasticity (Greenough and Chang, 1988; White et al., 1997; Hanover et al., 1999; Huang 
et al., 1999) varied from those at PND 10.  At this age, FXS mice exhibited significantly reduced 
expression of VEGF-A (Fig 2.3a; F(3,16)=11.91; p<0.05) and VEGF-B (Fig. 2.3b; F(3,16)=21.11; 
p<0.05) compared to WT mice.  Interestingly, WT mice also demonstrated a significant 
reduction in VEGF-B expression from PND 10; however, the reduction in FXS mice was more 
pronounced (Fig. 2.3b; F(3,16)=21.11; p<0.05).  VEGF-C, VEGF-D and PLGF did not show any 
differences between genotypes.   
At PND 35, the time point corresponding to the end of the rapid neuronal plasticity 
observed at PND 20 (Adriani et al., 2004), FXS and WT mice exhibited an age dependent 
reduction in VEGF-A (F(3,16)=35.18; p<0.05) and VEGF-B (F(3,16)=218.38; p<0.05), with pair-
wise t-test analyses demonstrating a similar reduction in VEGF-C (F(3,16)=22.06; p<0.05) and an 
increase in VEGF-D (F(3,16)=10.22; p<0.05).  Further analyses demonstrated that FXS mice 
exhibited significantly elevated amounts of VEGF-A (Fig. 2.3b; F(3,16)=11.91; p<0.05); however, 
VEGF-B and PLGF did not exhibit any significant differences compared to WT mice.  
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Interestingly, FXS mice had significantly elevated VEGF-C expression (Fig. 2.3c; t(4)=3.67; 
p<0.05) and reduced VEGF-D expression (Fig. 2.3d; t(4)=-4.37; p<0.05) compared to WT mice. 
Consistent with our prior studies in adult FXS mice (Galvan and Galvez, 2012; Belagodu 
et al., 2017), the current study found that PND 60 FXS mice exhibited significantly elevated 
VEGF-A expression compared to WT mice (Fig. 2.3a; F(3,16)=11.91; p<0.05).  Interestingly, 
VEGF-B (Fig. 2.3b; F(3,16)=21.11; p<0.05) and PLGF (Fig. 2.3e; F(2,12)=4.81; p<0.05) were both 
significantly reduced in FXS mice.  Contrary to that observed at PND 35, VEGF-C and VEGF-D 





Figure 2.3. VEGF Family Growth Factors’ expression is dysregulated in Fragile X mice (FXS) 
compared to their wildtype (WT) counterparts at key developmental time points (PND 10, 20, 
30, & 60).  All samples were run on the same gel to allow for direct comparison between time 
points.  a. VEGF-A expression in dissociated cortical hemispheres at developmental time points.   
b. VEGF-B expression in dissociated cortical hemispheres at developmental time points.  c. 
VEGF-C expression in dissociated cortical hemispheres at developmental time points.  d. VEGF-
D expression in dissociated cortical hemispheres at developmental time points.  e. PLGF 
expression in dissociated cortical hemispheres at developmental time points.  *<0.05 for 




With this dysregulation of the VEGF family members, each of the three primary 
receptors were also analyzed.  Interestingly, besides a change with age [VEGFR1 (Fig. 2.4a; 
F(3,16)=9.99; p<0.05), VEGFR2 (Fig. 2.4b; F(3,16)=55.36; p<0.05), VEGFR3 (Fig. 2.4c; 
F(3,16)=12.84; p<0.05)], there were not many notable differences across genotypes for any of the 
three main VEGF receptors .  VEGFR3 was the only receptor that demonstrated a significant 
age*geno interaction (Fig. 2.4c; F(3,16)=4.45; p<0.05).  As above we will now discuss individual 
pair-wise comparisons at each age to further elucidate specific FXS developmental 
abnormalities. 
At PND 10 FXS had significantly elevated VEGFR3 expression (Fig. 2.4c; F(3,16)=4.45; 
p<0.05).  At PND 20 there were no significant differences in any of the receptors in FXS mice.  
At PND 35 individual pair-wise t-tests demonstrated that both VEGFR1 (Fig. 2.4a; t(4)=5.56; 
p<0.05) and VEGFR2 (Fig. 2.4b; t(4)=2.8; p<0.05) were significantly elevated in FXS compared 






Figure 2.4. . VEGF Family Receptors’ expression is dysregulated in Fragile X mice (FXS) 
compared to their wildtype (WT) counterparts at key developmental time points (PND 10, 20, 
30, & 60).  All samples were run on the same gel to allow for direct comparison between time 
points.  a. VEGFR1 expression in dissociated cortical hemispheres at developmental time points.  
b. VEGFR2 expression in dissociated cortical hemispheres at developmental time points.  c. 
VEGFR3 expression in dissociated cortical hemispheres at developmental time points.  *<0.05 




Our prior studies have demonstrated that FXS is associated with adult abnormalities in 
both vascular density and VEGF-A expression (Galvan and Galvez, 2012; Belagodu et al., 
2017).  More importantly, we have shown that decreasing VEGF-A to WT levels can alleviate 
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some FXS abnormalities (Belagodu et al., 2017).  However, FXS is a developmental disorder 
and there are multiple VEGF proteins and receptors that could mediate FXS abnormalities at 
these developmental time points.  The current study set out to examine the developmental 
expression for these VEGF proteins, their receptors, and the underlying neocortical vascular 
density in FXS to determine their potential for mediating FXS abnormalities. 
At PND 10 we did not observe any significant differences in BVD in FXS mice but did 
detect several interesting differences in the various VEGF family members and receptors.  
VEGF-D was found to be reduced in FXS compared to WT mice (Fig. 2.3d).  Interestingly, 
VEGF-D is believed to primarily affect lymphangiogenesis and only have a minor role in 
vasculogenesis (Jeltsch et al., 1997; Veikkola et al., 2001; Karkkainen et al., 2002).  Although it 
was previously believed that the brain does not have lymphatic vasculature (Galea et al., 2007), 
recent studies have demonstrated the presence of lymphatic vasculature in the meninges 
(Aspelund et al., 2015; Louveau et al., 2015).  This lymphatic vasculature has been proposed to 
function in concert with the glymphatic system to act as a drainage for clearing by-products 
through CSF draining across the parenchyma (Iliff et al., 2012).  Collectively these studies 
suggest that the development of this drainage system may be impaired in FXS.  Interestingly, our 
study also found that VEGFR3 (Flt-4), a VEGF-D receptor (Joukov et al., 1996; Achen et al., 
1998), was upregulated in FXS mice.  This increased VEGFR3 expression could be an indication 
of  a compensatory mechanism initiated by the reduced VEGF-D expression.  VEGFR3’s 
primary role is with lymphangiogenesis, but also plays a critical role in the development and 
plasticity of vascular networks during embryogenesis (Dumont et al., 1998) (Kukk et al., 1996; 
Paavonen et al., 2000; Alitalo and Carmeliet, 2002; Laakkonen et al., 2007).   
37 
 
In addition to altered expression of VEGF-D and VEGFR3, VEGF-B was found to be 
significantly elevated in FXS mice at PND 10 (Fig. 2.3b). VEGF-B has been shown to be heavily 
involved in cell adhesion, migration and regulation of the extracellular membrane degradative 
process (Olofsson et al., 1998).  This reduced VEGF-B expression could result in a lack of or 
abnormal cellular migration in FXS, hindering proper neuronal development.  Interestingly, 
studies have demonstrated that the developmental switch of GABAergic transmission from 
depolarizing to hyperpolarizing is delayed during this time period (WT at ~PND 9 and FXS at 
~PND 14) (He et al., 2014).  Although the current study does not allow for a detailed analysis of 
the effects of reduced VEGF-B expression at this age, these findings suggest that this expression 
profile could hinder appropriate migration and formation of necessary neuronal connections 
delaying neuronal development in FXS. 
At PND 20 WT mice exhibited a significant increase in BVD that would directly 
correlate with and provide the appropriate nutrient levels for the robust global dendritic and 
synaptic plasticity occurring at this time point (Greenough and Chang, 1988; White et al., 1997; 
Hanover et al., 1999; Huang et al., 1999; Dahlhaus et al., 2011; Levelt and Hubener, 2012).  
Interestingly, FXS mice did not exhibit this developmental increase and had significantly 
reduced BVD compared to WT mice at this age (Fig. 2.2).  This absence of increased BVD in 
FXS was consistent with our subsequent examination of VEGF expression.  At PND 20, both 
VEGF-A and VEGF-B were significantly reduced in FXS compared WT mice (Fig. 2.3a & Fig. 
2.3b).  VEGF-A is the most prominent regulator of vascular growth, with increased expression 
inducing angiogenesis and vasculogenesis (Neufeld et al., 1999; Josko et al., 2000; Kunkel et al., 
2001; Carmeliet and Storkebaum, 2002).  Likewise, as discussed above, VEGF-B is critically 
involved in cell adhesion, migration and membrane degradation (Olofsson et al., 1998), cellular 
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processes that are critically involved in various aspects of vascular growth.  Consistent with our 
findings, WT mice have been shown to exhibit a drastic increase in neuronal brain VEGF 
expression at PND 20 (Ogunshola et al., 2000).  Interestingly, our examination of VEGF receptor 
expression failed to detect any differences at this age.  These findings suggest that the reduced 
VEGF-A and VEGF-B expression in FXS are resulting in a dysregulation, overall decrease rate 
of vascularization, and the observed decrease BVD at this time point.  Reduced BVD, potentially 
starving neurons of needed nutrients for proper neuronal development, could be an underlying 
cause for neuronal and cognitive abnormalities in FXS.  Future studies will need to explore this 
relationship and the potential beneficial effects of modulating VEGF expression at this early 
developmental time point. 
Unlike the distinct vascularization properties observed at PND 20, at PND 35 there were 
no significant differences in BVD between genotypes (Fig. 2.2).  PND 35 in male rodents is a 
complex time point as it corresponds to mid-adolescence, a time of sexual maturity, an end to 
ocular dominance critical period plasticity, and the end of the extensive neuronal plasticity 
observed at PND 20 (Vergouwen et al., 1993; Adriani et al., 2004; Dahlhaus et al., 2011; Levelt 
and Hubener, 2012).  Interestingly, VEGF-A, the main angiogenic factor, was significantly 
elevated in FXS mice at this time point (Fig. 2.3a).  This VEGF-A over expression in FXS could 
be a result of compensatory mechanisms originating from the lack of increased BVD expression 
at PND 20 or due to delayed neuronal development in FXS (Till et al., 2012; He et al., 2014).   
Consistent with the increased VEGF-A expression, FXS mice also exhibited increased 
expression of both VEGFR1 and VEGFR2 (Fig. 2.4a & Fig. 2.4b) [receptors that are activated 
by VEGF-A (de Vries et al., 1992)].  VEGFR1 has been shown to be important for normal 
vascular development as genetic knockouts result in excessive hemangioblast proliferation and a 
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reduction in the organization of vascular components (Fong et al., 1995).  VEGFR1 is also found 
on astrocytes, and is suggested to aid in overall astroglial expression of various growth factors 
(Krum et al., 2008; Koyama et al., 2014).  Interestingly, non-endothelial VEGF production shifts 
to a more glial origin at this time, and progresses through development (Ogunshola et al., 2000).  
This shift in origin and production could account for the harmonious increase in astrocyte 
VEGFR1 receptors and its subsequent activators.  Furthermore, this observation could suggest a 
dysregulation in glial/neuron ratios during FXS development, warranting further investigation.  
VEGFR2 has been shown to be the primary driver of angiogenesis, microvascular permeability 
(Dvorak, 2002), and is heavily involved with various aspects of endothelial cells such as 
proliferation and survival (Millauer et al., 1993; Zeng et al., 2001).  There is also growing 
evidence that VEGFR2 (primarily through VEGF-A stimulation) is heavily involved with 
modulating neuronal properties such as increased axonal and neurite outgrowth (Silverman et al., 
1999; Sondell et al., 1999; Sondell et al., 2000; Jin et al., 2002).  Interestingly, our study also 
found that FXS mice exhibited increased VEGF-C (Fig. 2.3c) but decreased VEGF-D (Fig. 2.3d) 
expression.  Both VEGF-C and VEGF-D can have similar functions as they both bind to 
VEGFR2 and VEGFR3 (Jeltsch et al., 1997; Veikkola et al., 2001; Karkkainen et al., 2002).  
Thus this bi-directional expression could be a form of reciprocal compensatory mechanisms. 
Consistent with our prior studies in young adults (Galvan and Galvez, 2012; Belagodu et 
al., 2017), the current study found that FXS mice had significantly elevated BVD and VEGF-A 
expression at PND 60 (Fig. 2.2 & Fig. 2.3).  As discussed in our prior studies (Belagodu et al., 
2017), FXS increased VEGF-A expression is the most likely cause for the elevated BVD density; 
however, various FXS abnormalities also exist at this age and could be either caused by or 
contribute to these VEGF-A and BVD abnormalities.  At this age numerous studies have 
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demonstrated an excess presence of long immature appearing dendritic spines with decreased 
presence of short mature appearing dendritic spines in various brain regions (Irwin et al., 2001; 
Galvez and Greenough, 2005).  Furthermore, studies have suggested that this dendritic spine 
abnormality is a direct result of increased dendritic immature spine turnover in FXS mice (Pan et 
al., 2010).  Interestingly, excessive dendritic spine motility would result in elevated metabolic 
demands and subsequent angiogenesis (Zhang et al., 2010) consistent with what we observed in 
FXS mice.  Furthermore, as discussed above and in our prior study (Belagodu et al., 2017), 
elevated VEGF-A has been shown to induce neurite outgrowth and may play a role in 
stimulating increased FXS dendritic spine motility. These findings, along with our prior studies 
(Belagodu et al., 2017) suggest that the FXS vascular and VEGF-A abnormalities are a result of 
or cause for many FXS abnormalities.  Interestingly, in addition to exhibiting elevated VEGF-A 
expression, FXS mice were found to have significantly reduced VEGF-B and PLGF expression 
compared to WT mice (Fig. 2.3b & Fig. 2.3d).  Although it is difficult to discern the cause for 
this reduction, it could be due to compensatory mechanisms as a result of the elevated BVD and 
VEGF-A expression.  Additional studies will be needed to better elucidate the cause for and 
effect of these altered growth factor expressions on FXS abnormalities. 
The current study elegantly demonstrates that BVD, the growth factors mediating 
vascular growth and their subsequent receptors exhibit a complex expression pattern that is often 
disrupted in FXS.  As discussed above, this abnormal developmental expression pattern in FXS 
could be a result of or cause many FXS abnormalities; thus providing a better understanding of 
FXS abnormalities over development.  Furthermore, as we have previously demonstrated with 
VEGF-A (Belagodu et al., 2017), correction of these abnormal developmental expression 
patterns in FXS can provide new sites and time points for therapeutic interventions. 
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CHAPTER 3: BLOCKING ELEVATED VEGF-A ATTENUATES NON- 
 




Fragile X syndrome (FXS) is the most common form of inherited mental retardation.  In 
exploring abnormalities associated with the syndrome, we have recently demonstrated abnormal 
vascular density in a FXS mouse model (Galvan and Galvez, 2012).  One of the most prominent 
regulators of vascular growth is VEGF-A (Vascular Endothelial Growth Factor A), suggesting 
that FXS is associated with abnormal VEGF-A expression.  In addition to its role in vascular 
regulation, VEGF-A also induces cellular changes such as increasing cell proliferation, and 
axonal and neurite outgrowth independent of its effects on vasculature.  These VEGF-A induced 
cellular changes are consistent with FXS abnormalities such as increased axonal material, 
dendritic spine density, and cell proliferation.  In support of these findings, the following study 
demonstrated that FXS mice exhibit increased expression of VEGF-A in brain.  These studies 
suggest that increased VEGF-A expression in FXS is contributing to non-vascular FXS 
abnormalities.  To explore the role of VEGF-A in mediating non-vascular FXS abnormalities, 
the monoclonal antibody Bevacizumab was used to block free VEGF-A.  Bevacizumab treatment 
was found to decrease FXS Synapsin-1 expression, a presynaptic marker for synapse density, 
and reduce FXS testicle weight to control levels.  Blocking VEGF-A also alleviated FXS 
abnormalities on novel object recognition, a test of cognitive performance.  These findings 
demonstrate that VEGF-A is elevated in FXS brain and suggest that its expression promotes non-











Fragile X Syndrome (FXS) is the leading form of inherited mental retardation and the 
most common known single gene cause for autism spectrum disorder (Cornish et al., 2008).  
Although the cause for the syndrome [transcriptional silencing of FMR1, the gene that codes for 
the Fragile X Mental Retardation Protein (FMRP)] is known (Pieretti et al., 1991; Verkerk et al., 
1991), our current understanding of the mechanisms mediating the behavioral and anatomical 
deficits are not understood.  In exploring FXS abnormalities, studies in a mouse model of the 
syndrome have demonstrated increased neocortical blood vasculature (Galvan and Galvez, 
2012).  These findings are consistent with reports from FXS patients demonstrating abnormal 
cerebral blood profusion (Balci et al., 2006; Kabakus et al., 2006) and suggest abnormal vascular 
development in FXS.  One of the most prominent regulators of vascular growth, with increased 
expression being synonymous with increased vasculature, is VEGF-A (Vasculature Endothelial 
Growth Factor A) (Neufeld et al., 1999).  These studies suggest that VEGF-A expression is 
elevated in FXS. 
In support of this hypothesis, molecular studies have further suggested that VEGF-A 
expression is elevated in FXS.  One of the most prominent theories of FMRP function has 
suggested that it regulates mGluR (metabotropic glutamate receptor) dependent synthesis of 
various proteins through mTORC1 (mammalian target of rapamycin) activation (Bear et al., 
2004; Sharma et al., 2010).  mTORC1 is a complex of proteins that mediate activation of various 
cellular substrates and exhibits elevated phosphorylation in FXS (Sharma et al., 2010; Hoeffer et 
al., 2012).  Interestingly, mTORC1 has been shown to mediate activation of HIF1α (hypoxia 
inducible factor 1, alpha), a transcription factor that promotes VEGF-A transcription (Brugarolas 
et al., 2003; Dodd et al., 2015).  Consistent with these findings, blocking mTORC1 in cancer 
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cells decreases VEGF-A expression (Li et al., 2015). These findings suggest that in FXS, an 
absence of FMRP, resulting in increased mTORC1 phosphorylation, would subsequently 
phosphorylate HIF1α resulting in increased VEGF-A production.  This mechanism would further 
suggest that VEGF-A expression is elevated and the most likely cause for increased vasculature 
in FXS (Galvan and Galvez, 2012). 
In addition to its primary role in angiogenesis, recent studies have demonstrated that 
VEGF-A can alter neuronal properties independent of vasculature.  Specifically, studies have 
shown that VEGF-A can increase neuronal survival and proliferation (Sondell et al., 1999; 
Matsuzaki et al., 2001; Jin et al., 2002).  Furthermore, VEGF-A stimulation of cultured neurons, 
in the absence of blood vessels, induces axonal outgrowth (Sondell et al., 1999; Sondell et al., 
2000) and dendritic/neurite growth (Silverman et al., 1999; Jin et al., 2002).  In further support of 
a neuronal role for VEGF-A, anatomical studies have characterized VEGF-A receptors 
(VEGFR2/Flk-1) on dorsal root ganglia neurons and HN33 cells (an immortalized hippocampal 
neuronal cell line), suggesting that VEGF-A can directly alter neuronal properties independent of 
its role on vasculature (Jin et al., 2000; Sondell et al., 2000; Jin et al., 2002).  These studies 
suggest that in addition to its prominent role in vascular growth, VEGF-A also acts directly on 
neurons altering various neuronal properties such as cell proliferation, axonal sprouting, and 
neurite outgrowth. 
Interestingly, these VEGF-A induced cellular properties are consistent with many FXS 
abnormalities.  Studies have demonstrated that similar to VEGF-A induced increased cell 
proliferation (Sondell et al., 1999; Matsuzaki et al., 2001; Jin et al., 2002), FXS has been 
associated with increased proliferation of Sertoli cells (Slegtenhorst-Eegdeman et al., 1998) and 
hippocampal neurons (Luo et al., 2010).  Furthermore, consistent with VEGF-A induced 
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increased axonal and neurite outgrowth (Silverman et al., 1999; Sondell et al., 1999; Sondell et 
al., 2000; Jin et al., 2002), excessive axonal growth and increased dendritic material have been 
observed in a drosophila and mouse model of FXS (Galvez et al., 2003; Antar et al., 2005).  Also 
in line with these finding FXS neurons have been shown to exhibit an abundance of long-thin 
dendritic spines (Irwin et al., 2002; Galvez and Greenough, 2005; Grossman et al., 2006).  
Interestingly, two photon FXS studies have further demonstrated that this increase in dendritic 
spine density is due to an increase in dendritic spine formation, suggesting that an unknown 
factor is actively stimulating dendritic spine production in FXS (Pan et al., 2010).  These 
findings, along with the fact that VEGF-A stimulates neurite outgrowth (Silverman et al., 1999; 
Jin et al., 2002), suggests that elevated VEGF-A expression in FXS is stimulating dendritic spine 
production and possibly other neuronal anatomical abnormalities. 
The following study demonstrates that VEGF-A is elevated in FXS brains and suggests 
that this increase is due to an mTORC1 dependent pathway.  To explore the role of VEGF-A in 
mediating non-vascular FXS abnormalities, VEGF-A was blocked and found to alleviate both 
behavioral and anatomical FXS abnormalities.  These studies provide the first account for the 
role of VEGF-A in contributing towards FXS abnormalities.   
Methods & Analysis  
 
Housing and Care of Animals   
 
Adult (PND 60) male C57/B6 FMR1 knockout (FXS) and wildtype (WT) mice were 
used.  Mice were housed in standard laboratory conditions (12 hr-12 hr light/dark cycle with 





For analysis of VEGF-A expression, dissected cortical hemispheres, including cortical 
white matter and hippocampus (referred to as cortical hemispheres from this point on) from FXS 
(n=3) and WT (n=3) mice were homogenized and protein concentration estimated via 
bicinchonic acid assay (Thermo Scientific).  Protein (40 µg) in a 1:1 loading buffer (475 µl 
Laemmli + 25 µl βME) ratio was loaded and run on a 4-15% electrophoresis gel (Biorad) at 100 
V for 10 min followed by 200 V for 35 min.  The separated proteins were then transferred to a 
nitrocellulose membrane at 100 V for 1 hr, blocked with 5% milk in TBS-T (Tris Buffered 
Saline with 0.05% Tween 20) and probed with VEGF-A antibody (1:1000; Santa Cruz) 
overnight at 4°C.  The membrane was then washed and incubated in anti-rabbit secondary 
antibody (1:1000; Cell Signaling Technology) for 2 hr prior to chemiluminescent substrate 
exposure for 5 min and imaged via a BioRad ChemiDoc Touch Gel Imaging System (BioRad).  
Once imaged, blots were re-probed for GAPDH (1:1000; Santa Cruz) as a loading control.  The 
relative intensity of VEGF-A was determined by dividing its optical density, determined using 
Image Lab v5.2.1 (BioRad), by GAPDH.  GAPDH has been used in previous FXS studies as an 
effective loading control (Yu et al., 2013; Pretto et al., 2014; von Leden et al., 2014). 
 To explore the proposed mechanism for the increased VEGF-A expression and the 
dependency on mTORC1 activation in FXS, brain slices from FXS (n=3) mice were treated with 
rapamycin followed by Western Blot analysis of VEGF-A expression.  For collection of brain 
slices, mice were transcardially perfused with an ice cold high sucrose slicing solution (206 mM 
sucrose, 10.0mM MgCl2, 11.0 mM glucose, 1.25 mM NaH2PO4, 26 mM NaHCO3, 0.5 mM 
CaCl2, and 2.5 mM KCl at ph 7.4) and brains sectioned via vibrating tissue slicer (300 microns) 
into a holding chamber with oxygenated artificial cerebrospinal fluid (126 mM NaCl, 2.0 mM 
MgCl2, 10.0 mM glucose, 1.25 mM NaH2PO4, 26 mM NaHCO3, 2.0 mM CaCl2, and 2.5 mM 
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KCl at ph 7.4).  The sections were also cut in half and stored in separate chambers to allow for 
within animal control of rapamycin treatment.  After a 3-4 hour incubation at 37°C in a cell 
culture incubator maintained at >80% humidity and 5% CO2, half of each brain section was 
treated with 50 nM rapamycin or equivalent DMSO vehicle for 30 min.  After drug treatment, 
the sections from each animal and hemisphere were pooled, homogenized and examined for 
VEGF-A expression with Western Blot detection as described above. 
Blocking VEGF-A  
 
To determine the role of VEGF-A in mediating FXS abnormalities, its ability to bind to 
its receptor was blocked using Bevacizumab (Genentech).  Bevacizumab is a monoclonal 
antibody that binds to free-floating VEGF-A preventing it from binding with its receptor.  To 
determine Bevacizumab’s ability to block VEGF-A in brain, WT (n=6) and FXS (n=6) mice 
were given 5 mg/kg Bevacizumab or Saline IP every other day for 10 days.  This dose has been 
shown to attenuate VEGF-induced angiogenesis in mouse brain (Lu et al., 2012; Walker et al., 
2012).  VEGF-A expression in dissected cortical hemispheres was then examined with Western 
Blot analyses. Samples were prepared and processed as described above on a large 10% 
electrophoresis gel at 150 V for 1 hr followed by 200 V for 4 hrs.  The separated proteins were 
then transferred to a nitrocellulose membrane at 20 V at 100 mA overnight.  The membrane was 
then probed for VEGF-A and GAPDH with Western Blot detection as described above.  
Synapse Expression   
 
To examine the role of VEGF-A in mediating synapse density, mice were given 
Bevacizumab as outlined above.  The day following the last injection, mice were either 
processed for Western Blot analyses of VEGF-A as described above or transcardially perfused 
for Immunohistochemical analyses.  For Western Blot analyses dissected cortical hemispheres 
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were examined from WT (n=6) and FXS (n=6) mice for Synapsin-1 expression.  Synapsin-1 is a 
synaptic vesicle binding protein whose expression correlates with synapse number (Sudhof et al., 
1989; Cesca et al., 2010).  Synapsin-1 antibody (Sigma) was probed at 1:1000 dilution, incubated 
overnight and imaged along with GAPDH to control for loading differences.  For 
Immunohistochemical analyses six sections (30 µm) spanning primary visual cortex (V1) (FXS 
Saline n=5, FXS Bevacizumab n=4, WT Saline n=5, WT Bevacizumab n=4) and CA1 of 
hippocampus (FXS Saline n=4, FXS Bevacizumab n=5, WT Saline n=5, WT Bevacizumab n=5) 
were examined.  V1 was selected because in rodents it exhibits many forms of experience-
induced plasticity that were previously believed to only be found in higher processing regions of 
the cortex.  For example V1 neurons exhibit stimulus familiarity (Sawtell et al., 2003; Frenkel et 
al., 2006; Cooke and Bear, 2010), reward-timing prediction (Shuler and Bear, 2006; Chubykin et 
al., 2013), and spatiotemporal sequence learning (Gavornik and Bear, 2014).  As a result studies 
have recently utilized plasticity in V1 as an indicator of cognitive health for various neurological 
disorders (Cooke and Bear, 2012; Gavornik and Bear, 2014).  Furthermore, V1 is the brain 
region where FXS neuronal and vascular abnormalities have been the most extensively examined 
(Irwin et al., 2002; Galvan and Galvez, 2012) making it a suitable structure for examining FXS 
abnormalities.  CA1 was selected due to its well established link with cognition (Zola-Morgan et 
al., 1986) and the fact that it exhibits FXS dendritic spine abnormalities (Grossman et al., 2006).  
 For staining, sections were incubated in Synapsin-1 antibody (1:500; Sigma) overnight at 
4°C followed by a 2 hr biotinulated anti-rabbit secondary antibody incubation at room 
temperature (1:100; Jackson ImmunoResearch).  Synapsin-1 expression was visualized through 
avidin-biotin amplification (Vector) and nickel enhanced DAB detection (0.5 mg/ml DAB, 6.95 
mg/ml nickel ammonium sulfate, 0.033 µl/ml 30% hydrogen peroxide).  Sections were imaged 
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on an Olympus BX50 microscope with a Zeiss AxioCam ICc1 camera at 20x magnification with 
AxioVision ver4.8.1.  The number of Synapsin-1 positive puncta per area was quantified across 
all layers in V1 and in the apical dendritic field of CA1 of the hippocampus using the particle 
analysis tool on ImageJ (http://rsbweb.nih.gov/ij/docs/guide/146-30.html).  To accurately 
determine the density of Synapsin-1 staining in the neuropil the area with blood vessels was 
removed from the analysis. To determine if the absence of FMRP altered the size of V1 or CA1, 
volumetric analyses were conducted.  Briefly, the total area of the region was determined on 
adjacent evenly spaced cresyl violet stained sections from each brain by tracing the region on 
ImageJ. These areas were then multiplied by the distance between each section to create an 
estimation of the volume between sections.  This number was then summed with each volume 
between each of the sections, to provide an overall estimation of the total volume of V1 and 
CA1.    
Testicle Weight 
 
To elucidate the role of VEGF-A in modulating FXS testicle weight, FXS (n=10) and 
WT (n=5) mice were given Bevacizumab or Saline via the dosing scheme outlined above.  The 
day following the last injection, testicles were removed and post-fixed in 4% paraformaldehyde 
for 24 hr.  FXS males exhibit macroorchidism as a result of increased Sertoli cell proliferation 
(Slegtenhorst-Eegdeman et al., 1998).  After post-fixing, testicles were desiccated for 2 days and 
weighed.  Testicular weight has been shown to be a viable metric to assess macroorchidism in 
adult FXS mice (Kooy et al., 1996).  For statistical analyses each testicle was considered an 
individual unit. 




To determine the contribution of VEGF-A to FXS behavioral and cognitive deficits, mice 
were given Bevacizumab or Saline (FXS Saline n=7, FXS Bevacizumab n=9, WT Saline n=7, 
WT Bevacizumab n=9) as outlined above and tested for hyperactivity and novel object 
recognition.  Using a modified protocol (Ventura et al., 2004), mice were habituated to the 
training chamber (16.5”L x 8.5” W x 8” H) with no objects for 10 min on the day following the 
last injection.  Between trials, to decrease the influence of scent marking, the cage was wiped 
down with 70% ethanol and allowed to dry before starting the next trial.  Hyperactivity was 
assessed during habituation.  To assess hyperactivity, video recordings of the mice were obtained 
and the distance traveled over 10 minutes was measured with Anymaze (v4.98).  The following 
day (Training), mice were exposed to two of the same objects (randomly assigned, two beakers 
or two plastic egg shells) for 10 min.  Percent time exploring the objects (direct whisking or 
sniffing) was determined using the following calculation: (time exploring the objects/total 
training time)*100.  Preference for a specific side of the training chamber (Left vs. Right) was 
determined using the following calculation: (time spent on each side/total training time)*100.  
On the third day (Testing), one of the objects was randomly replaced with a novel object and the 
time spent interacting with each (direct whisking or sniffing) was recorded for 10 min.  Percent 
interaction time for each object was determined via: (interaction with object/sum of total 
interaction with both objects)*100.  Note 50% delineates equal exploration of both objects.  On 
average mice spent 32.9 sec interacting with the objects.  Finally the discrimination index for the 
novel object was determined via: [(interaction with novel object–interaction with familiar 
object)/interaction with familiar object]*100.  Four mice (1 from each group) spent less than 10 
sec interacting with any of the objects during the Testing Stage and were thus removed from the 






The analysis of VEGF-A expression in WT vs FXS and FXS rapamycin treated vs non-
treated were conducted with a paired T-Test with equal variance on SAS 
(http://www.sas.com/en_us/home.html).  All additional statistical analyses were conducted with 
a 2-way mixed model ANOVA on SAS with either genotype and/or drug as between subject 
factors.  For novel object recognition, object (novel vs. familiar) was treated as a within subject 
factor.  
Results   
 
VEGF-A brain expression in FXS was found to be elevated compared to WT mice.  FXS 
dissected cortical hemispheres were found to have 45.6% more VEGF-A expression than WT 
mice (Fig. 3.1a; t(4)=3.06; p<0.05).  Note, there was no significant difference in GAPDH 
(loading control) expression in the Western Blot analysis or any of the subsequent analyses 
across any of the groups (data not shown).  This increased VEGF-A expression in FXS is 
consistent with the proposed molecular pathway (Fig. 3.1c).  To further investigate the proposed 
molecular pathway, FXS brain sections were treated with rapamycin to block mTORC1 
activation followed by analysis of VEGF-A expression.  This study found that blocking 
mTORC1 activation for 30 minutes decreased VEGF-A expression in FXS brain 13% (Fig. 3.1b; 
t(4)=3.10; p<0.05).  These findings, although cannot discount a possible mTORC1 independent 
pathway contributing towards FXS VEGF-A expression, suggest that the increased VEGF-A 





Figure 3.1. VEGF-A expression is elevated in Fragile X brain.  a. VEGF-A expression in 
dissected cortical hemispheres.  Adult FXS mice have significantly more VEGF-A expression 
than WT mice.  GAPDH was used as a loading control. b. VEGF-A expression in FXS is 
mediated by an mTORC1 dependent pathway.  Treatment of adjacent coronal hemispheres with 
Rapamycin to block mTORC1 activity for 30 min significantly decreased VEGF-A expression in 
FXS brain slices.  GAPDH was used as a loading control.  Rapa.=Rapamycin  c. Schematic of a 
proposed molecular pathway for VEGF-A production involving the Fragile X Mental 
Retardation Protein (FMRP), the protein that is absent in FXS.  Arrows=activation.  
Perpendicular line=inhibition.  Solid lines=known interactions.  Dotted lines=proposed 
interactions.  For a detailed description of the mGluR/FMRP pathway see (Bear et al., 2004; 
Santoro et al., 2012). *<0.05 
 
To explore the role of VEGF-A in mediating FXS abnormalities, VEGF-A’s ability to 
bind to its receptor was blocked with Bevacizumab.  Blocking of VEGF-A was found to 
significantly reduced VEGF-A expression in dissected cortical hemispheres of FXS mice (Fig. 
3.2a; F(3,11)=12.72; p<0.05).  These findings demonstrate that Bevacizumab can be used to 
explore the role of VEGF-A in FXS brain abnormalities.   
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One of the most prevalent FXS neuronal abnormality is increased dendritic spine density.  
To examine synapse properties, we demonstrated with Western Blot analyses, that Synapsin-1 
was significantly increased in FXS dissected cortical hemispheres compared to WT mice (Fig. 
3.2b; F(3,8)=6.66; p<0.05).  Subsequent region specific analyses demonstrated that Synapsin-1 
was significantly increased in FXS V1 (82%) and CA1 (60%) compared to WT controls.  
Interestingly, these findings are not consistent with a prior study examining Synapsin staining in 
FXS (Li et al., 2002).  Possible differences could be due to the quantification methods used; 
however, our findings are consistent with previous FXS anatomical dendritic spine studies (Irwin 
et al., 2002; Galvez and Greenough, 2005; Grossman et al., 2006; Pan et al., 2010).  In addition 
to replicating the FXS dendritic spine abnormality, our Synapsin-1 analyses demonstrated that 
Bevacizumab treatment significantly decreased Synapsin-1 density in FXS cortical hemispheres, 
V1 and CA1 [Fig. 3.2b; Cortex F(3,8)=6.66; p<0.05; Fig. 3.2e; V1 (F(3,12)=4.10;p<0.05); Fig. 3.2f; 
CA1 (F(3,15)=3.86;p<0.05)].  Note, Bevacizumab did not have a significant effect on Synapsin-1 
in WT mice.  Furthermore, volumetric analyses of V1 and CA1 demonstrated no significant 
differences between treatment groups (V1 Fig. 3.2g & CA1 Fig. 3.2h), demonstrating that the 
observed differences in Synapsin-1 density are not due to Bevacizumab induced changes in the 
volume of these brain regions.  These findings strongly suggest that elevated VEGF-A 













Figure 3.2. Bevacizumab decreases VEGF-A and Synapsin-1 (SYN) in Fragile X.  a. VEGF-A 




Figure 3.2 (cont.). Bevacizumab decreases VEGF-A and Synapsin-1 (SYN) in Fragile X.  a. 
VEGF-A expression in dissected cortical hemispheres following 10 days of Bevacizumab 
treatment.  Bevacizumab treatment significantly reduced VEGF-A expression in adult FXS mice.  
GAPDH was used as a loading control.  b. Synapsin-1 expression in treatment groups.  
Bevacizumab treatment significantly reduced SYN expression in adult FXS mice.  GAPDH was 
used as a loading control.  c. Immunohistochemical expression of Synapsin-1 (dark punctated 
staining pattern) in primary visual cortex (V1) from treatment groups.  Note, FXS saline treated 
have more dark punctated staining than WT mice and Bevacizumab treatment decreases that 
amount of dark punctated staining to WT levels.  d. Immunohistochemical expression of 
Synapsin-1 (dark punctated staining pattern) in CA1 from treatment groups.  Note, FXS saline 
treated have more dark punctated staining than WT mice and Bevacizumab treatment decreases 
that amount of dark punctated staining to WT levels.  e. Quantification of Synapsin-1 density in 
V1 following treatment with Bevacizumab.  Bevacizumab significantly decreased the density of 
V1 Synapsin-1 positive puncta in adult FXS mice.  f. Quantification of Synapsin-1 density in 
CA1 following treatment with Bevacizumab.  Bevacizumab significantly reduced the density of 
CA1 Synapsin-1 positive puncta in adult FXS mice.  Note, Bevacizumab did not significantly 
alter Synapsin-1 expression in WT V1 or CA1.  g. Volumetric analysis of V1 following 
treatment with Bevacizumab.  h. Volumetric analysis of CA1 following treatment with 
Bevacizumab.  Bevacizumab did not significantly alter the volume of V1 or CA1.  Scale bar 
=10µm Bevacizumab=Bev.  *<0.05 
 
In addition to neuronal abnormalities, macroorchidism has also been characterized as a 
prominent abnormality in FXS subjects.  Consistent with previous studies (Slegtenhorst-
Eegdeman et al., 1998) FXS mice exhibited a significant 20% increase in testicle weight 
compared to WT controls.  However, Bevacizumab treatment decreased FXS testicle weight 
11%, making them statistically indistinguishable from WT mice (Fig. 3.3a; F(3,26)=6.87;p<0.05).  
Note, Bevacizumab did not have a significant effect on testicle weight in WT mice.  These 






Figure 3.3. Blocking VEGF-A decreases FXS testicle weight.  a. Representative testicles from 
treatment groups. Scale bar=5 mm.  b. Quantification of testicle weight from adult mice treated 
with Bevacizumab.  Bevacizumab significantly reduced testicle weight in FXS mice.  Note, 
Bevacizumab did not significantly alter testicle weight in WT mice. Bevacizumab=Bev.  *<0.05 
 
Finally, to assess VEGF-A contribution towards FXS behavioral and cognitive 
abnormalities, mice were given Bevacizumab as outlined above and tested for hyperactivity and 
novel object recognition.  In line with previous findings (Bakker et al., 1994), FXS mice 
exhibited increased hyperactivity compared to WT mice (Fig. 3.4b; t(26)=3.00;p<0.05).  
Bevacizumab did not significantly alter activity levels in either FXS or WT mice. For novel 
object recognition, WT controls exhibited expected preferential exploration towards the novel vs. 
familiar object.  Likewise, consistent with previous studies, FXS Saline mice did not exhibit 
preferential exploration towards either object (Ventura et al., 2004; Bhattacharya et al., 2012; 
Seese et al., 2014).  However, Bevacizumab treated FXS, like WT mice, preferentially explored 
the novel vs. familiar object, suggesting that they remembered which object had been previously 
explored [Fig. 3.4c; Percent Interaction Time (F(1,14)=11.36;p<0.05), Fig. 3.4f; Discrimination 
Index (F(3,19)=4.68;p<0.05)]. 
As a behavioral control it was further determined that during training mice did not 
significantly differ in percent time exploring the objects (Fig. 3.4d).  However, all groups 
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exhibited a significant preference for the left side of the training chamber (Fig. 3.4c; 
t(48)=3.20;p<0.05), with no significant side by group interaction; suggesting that this could not 
account for any group differences.  These findings collectively suggest that blocking VEGF-A 





Figure 3.4. Blocking VEGF-A alleviates FXS novel object recognition (NOR) deficits.  a. NOR 
training protocol.  b. Amount of movement during habituation.  FXS mice had significantly more 
movement than WT mice.  Bevacizumab did not significantly alter the amount of movement for 
any of the groups.  c. Percent time spent in each side of the training chamber during training.  
Mice in all groups preferred the right side of the training chamber.  This preference was 
controlled for by randomly placing the novel object on either side of the training chamber during 
testing.  d. Percent time mice spent exploring objects during training.  There were no significant 
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Figure 3.4 (cont.): differences across groups.  e. Percent time spent interacting with each object 
during testing.  Bevacizumab increased adult FXS preference for the novel object, similar to WT 
mice.  Dotted line represents no preference.  f. Discrimination index for novel object interaction 
across treatment groups.  Bevacizumab alleviated FXS discrimination index deficit.  Note, 
Bevacizumab did not significantly alter any measured behaviors in WT mice.  




Fragile X Syndrome is the leading form of inherited mental retardation.  It is caused by 
transcriptional silencing of a single gene, FMR1; however, the specific mechanisms by which 
this genetic mutation causes FXS abnormalities are currently unknown.  The current study 
explored a novel mechanism contributing towards FXS abnormalities, VEGF-A modulation.  
Historically VEGF-A has been shown to play a prominent role in vascular regulation, with 
increased expression being synonymous with increased vasculature (Josko et al., 2000).  
Consistent with these studies we previously demonstrated vascular abnormalities in V1 of adult 
FXS mice (Galvan and Galvez, 2012).  However, in addition to its vascular role, recent studies 
have demonstrated that VEGF-A can increase axon growth, cell survival and neurite outgrowth, 
consistent with abnormalities observed in FXS (excessive axonal material, increased 
neurogenesis, and increased number of immature dendritic spines); suggesting a role for VEGF-
A in mediating non-vascular FXS abnormalities (Slegtenhorst-Eegdeman et al., 1998; Silverman 
et al., 1999; Sondell et al., 1999; Jin et al., 2002; Pan et al., 2004; Pan et al., 2010). 
In exploring this mechanism, the current study demonstrated that VEGF-A expression is 
elevated in the cortex of FXS mice (Fig. 3.1a).  These findings, although novel for FXS and 
VEGF-A, are consistent with our current molecular understanding of FMRP function.  In FXS 
mTORC1 has been shown to exhibit increased phosphorylation/activation (Sharma et al., 2010).  
Furthermore, mTORC1 is a critical regulator of VEGF-A, with increased mTORC1 activation 
resulting in increased VEGF-A expression (Brugarolas et al., 2003; Dodd et al., 2015) (Fig. 
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3.1c).  Consistent with these findings, we demonstrated that blocking mTORC1 in FXS 
decreases VEGF-A expression (Fig. 3.1b), suggesting that increased mTORC1 phosphorylation 
in FXS would result in increased VEGF-A expression.  These studies collectively support our 
current finding of increased VEGF-A expression in FXS and suggest a role for VEGF-A in 
mediating FXS abnormalities.  
To explore the role of VEGF-A in mediating FXS abnormalities, our subsequent studies 
blocked VEGF-A and demonstrated decreased synapse density in FXS mice (Fig. 3.2b-h).  Note, 
these studies did not discern the effect of blocking VEGF-A on dendritic spine morphology in 
FXS.  Current studies in the lab are actively exploring this research direction.  However, our 
findings demonstrate that blocking VEGF-A can decrease elevated synapse density in FXS.  
Synapse abnormalities have been well documented in FXS (Irwin et al., 2002; Galvez and 
Greenough, 2005; Grossman et al., 2006); with studies suggesting that adult dendritic spine 
abnormalities are a result of increased dendritic spine proliferation (Pan et al., 2010).  These 
studies have suggested that an unknown factor stimulates dendritic spine proliferation in FXS.  
Consistent with these findings, VEGF-A stimulation of cultured neurons in the absence of blood 
vessels increases dendritic growth, axon length and axon density (Silverman et al., 1999; Sondell 
et al., 1999; Jin et al., 2002).  These findings collectively suggest that excessive brain VEGF-A 
in FXS stimulates dendritic spine proliferation, inducing FXS dendritic spine abnormalities.  
Many studies have suggested that FXS neuronal abnormalities such as increased dendritic 
spine density are an underlying cause for behavioral and cognitive abnormalities.  Based upon 
this rational, we demonstrated that blocking VEGF-A can alleviate FXS cognitive abnormalities 
using novel object recognition (Fig. 3.4e & f).  When provided with a choice, mice normally 
explore a novel object over a familiar object.  However, FXS mice do not preferentially explore 
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either object, suggesting that they do not remember prior exposure to the familiar object 
(Busquets-Garcia et al., 2013).  Blocking VEGF-A alleviates this behavioral abnormality in FXS.  
Furthermore, this behavioral effect cannot be explained due to changes in the total number of 
object interactions or hyperactivity, as blocking VEGF-A did not alter either of these behaviors 
(Fig. 3.4b & d).  These findings suggest that excessive VEGF-A production, possibly via VEGF-
A induced synapse abnormalities, contributes to FXS cognitive abnormalities.   
Although the mechanism for VEGF-A induced neuronal growth is still not fully 
understood, VEGF-A has been shown to predominantly bind to VEGFR1 and VEGFR2. Upon 
VEGF-A binding to VEGFR1, it activates PLC gamma (phospholipase C) that then 
phosphorylates DAG (diacylglycerol), which phosphorylates PKC (protein kinase C). PKC then 
alters various cellular processes including cell proliferation and vasopermeability. In contrast, 
when VEGF-A binds to VEGFR2 it activates Shc (SH2 domain protein C1) that then 
phosphorylates RAS (Rat sarcoma), which phosphorylates MAPK. This activation then also 
alters various cellular processes including gene expression and cell proliferation. More 
importantly, neuronal studies have suggested that activation of VEGFR2 and the MAPK 
pathway are primarily responsible for VEGF-A’s ability to modulate neuronal processes. For 
example, VEGF-A stimulation of superior cervical ganglia neurons which predominantly express 
VEGFR2 and neurophilin-1, induce axonal outgrowth and cell survival (Sondell et al., 1999). 
Furthermore, inhibiting VEGFR2 or MAPK prevents VEGF-A induced axon growth (Sondell et 
al., 1999; Sondell et al., 2000). These studies suggest that VEGF-A is mediating its neuronal 
effects in FXS through VEGFR2 and the MAPK pathway.  
Although VEGF-A has been shown to directly alter neuronal properties independent of 
vascular changes (Sondell et al., 1999), it is possible that the observed attenuation of FXS 
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abnormalities are not due to direct neuronal modulation, but rather due to indirect Bevacizumab 
induced VEGF-A modulation of vascular properties.  Blocking VEGF-A (via Bevacizumab) 
decreases VEGF-induced angiogenesis in control brains (Walker et al., 2012); however, its effect 
on already established vascularization in FXS has not been explored.  If decreasing VEGF-A 
expression decreases vascular density in FXS brain, decreased nutrients and other signaling 
factors being delivered via the blood stream could mediate some or all of the benefits observed.  
Interestingly, it should be noted that our prior studies demonstrated increased vasculature in aged 
FXS brains with only mild increases in adults (Galvan and Galvez, 2012), the age group 
examined in this study.  The mild increased vasculature observed in adult FXS brains suggests 
that abnormalities in vascular density alone could not completely account for the extensive FXS 
neuronal abnormalities observed at this age.  However, this does not preclude VEGF-A from 
acting directly on neurons.  Furthermore, our finding of increased VEGF-A expression in the 
absence of excessive vascular growth (Galvan and Galvez, 2012) suggests that a compensatory 
mechanism is reducing vasculature in FXS brains.  Current studies in the lab are actively 
exploring this and other possible mechanisms for the role of VEGF-A in FXS abnormalities.  
Although further studies will be needed to determine the specific mechanism by which blocking 
VEGF-A is able to attenuate these FXS abnormalities, the current studies strongly suggest that 
increased VEGF-A expression plays a role in mediating FXS neuronal abnormalities.   
Additionally, these studies demonstrate that reducing VEGF-A binding, irrespective of the 
mechanism, helps alleviate some FXS neuronal abnormalities. 
In addition to playing a role in FXS neuronal abnormalities, our studies suggest that 
excess VEGF-A expression is mediating other FXS abnormalities such as macroorchidism. 
Studies have shown that FXS is associated with increased testicle weight, due to increased 
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Sertoli cell proliferation (Slegtenhorst-Eegdeman et al., 1998).  Consistent with these findings, 
VEGF-A stimulation increases neuronal survival rate and proliferation of Schwann cells (Xiao et 
al., 2007).  These studies suggest that abnormal VEGF-A expression in FXS is mediating the 
increased Sertoli cell proliferation.  In support of this hypothesis, we demonstrated that blocking 
VEGF-A in FXS significantly reduced testicle weight (Fig. 3.3b).  These findings further suggest 
that excessive VEGF-A production in FXS plays a role in mediating both neuronal and non-
neuronal FXS abnormalities.   
 The aforementioned experiments demonstrate that blocking VEGF-A can alleviate FXS 
abnormalities in testicle weight, synapse density, and cognition.  Although the specific 
mechanism mediating these effects is still not fully understood, these studies elucidate a potential 
novel mechanism, VEGF-A modulation, for FXS abnormalities.  Furthermore, it is worth noting 
that the benefits following blocking of VEGF-A were observed in adult FXS, further suggesting 





CHAPTER 4: CHARACTERIZATION OF ULTRASONIC VOCALIZATIONS OF  
 




Fragile X Syndrome (FXS) is the leading form of inherited intellectual disability.  It is 
caused by the transcriptional silencing of FMR1, the gene which codes for the Fragile X Mental 
Retardation Protein (FMRP).  Patients that have FXS exhibit numerous behavioral and cognitive 
impairments, such as attention-deficit/hyperactivity disorder, obsessive compulsive disorder, and 
autistic-like behaviors.  In addition to these behavioral abnormalities, FXS patients have also 
been shown to exhibit various deficits in communication such as abnormal sentence structures, 
increased utterances, repetition of sounds and words, and reduced articulation.  These deficits 
can dramatically hinder communication for FXS patients, exacerbating learning and cognition 
impairments while decreasing their quality of life.  To examine the biological underpinnings of 
these communication abnormalities, studies have used a mouse model of the Fragile X 
Syndrome; however, these vocalization studies have resulted in inconsistent findings that often 
do not correlate with abnormalities observed in FXS patients.  Interestingly, a detailed 
examination of frequency modulated vocalizations that are believed to be a better assessment of 
rodent communication has never been conducted.  The following study used courtship separation 
to conduct a detailed examination of frequency modulated ultrasonic vocalizations (USV) in 
FXS mice.  Our analyses of frequency modulated USVs demonstrated that adult FXS mice 
exhibited longer phrases and more motifs.  Phrases are vocalizations consisting of multiple 
frequency modulated ultrasonic vocalizations, while motifs are repeated frequency modulated 
USV patterns.  Fragile X mice had a higher proportion of “u” syllables in all USVs and phrases 
while their wildtype counterparts preferred isolated “h” syllables.  Although the specific 
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importance of these syllables towards communication deficits still needs to be evaluated, these 
findings in production of USVs are consistent with the repetitive and perseverative speech 
patterns observed in FXS patients.  This study demonstrates that FXS mice can be used to study 
the underlying biological mechanism(s) mediating FXS vocalization abnormalities.  Note this 
study has already been published (Belagodu et al., 2016). 
Introduction 
 
 Fragile X Syndrome (FXS) is the leading form of inherited intellectual disability and the 
most common known single gene cause for Autism Spectrum Disorder (ASD) (Maenner et al., 
2013).  FXS is an X-linked disorder that generally results from the transcriptional silencing of 
FMR1, the gene which codes for the Fragile X Mental Retardation Protein (FMRP).  Normally 
the 5 untranslated region of FMR1 contains a CGG trinucleotide repeat of less than 50 repeats, 
whereas in FXS it contains more than 200 CGG repeats.  This extended trinucleotide repeat leads 
to hypermethylation and transcriptional silencing of FMR1 (McLennan et al., 2011; Santoro et 
al., 2012).  As a result, FXS patients exhibit many behavioral abnormalities consistent with those 
commonly observed in ASD, such as poor eye contact, hand flapping and/or hand biting, 
hyperactivity, impulsivity, and social anxiety (Miller et al., 1999; Kronk et al., 2010; Cordeiro et 
al., 2011). 
 In addition to these behavioral deficits, many studies have characterized various 
communication abnormalities in FXS patients.  For example, FXS patients exhibit a greater 
number of articulation errors often associated with dyspraxia as well as dysprosody (Borghgraef 
et al., 1987; Spiridogliozzi et al., 2000; Mirrett et al., 2003; Roberts et al., 2005).  They also 
often speak in rapid bursts of repeated words (Largo and Schinzel, 1985; Tierney et al., 2012), 
although they do not significantly differ from controls in the number of vocalizations produced 
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(Borghgraef et al., 1987).  Furthermore, FXS patients have been shown to exhibit a form of 
stuttering (disfluency) where they repeat components of speech (Lubs et al., 1984; Opitz and 
Sutherland, 1984; Rhoads, 1984; Vilkman et al., 1988). These disfluencies typically manifest in 
the initial component of the phrase or sentence resulting in a subpar structuring of sentences 
(Lubs et al., 1984; Opitz and Sutherland, 1984).  Such deficits in speech production can 
dramatically hinder communication with FXS patients, having detrimental consequences on 
subsequent learning, cognition and quality of life (Cornish et al., 2004). 
 In recent years the FXS mouse model has provided a vital tool for understanding the 
anatomical and molecular bases for many deficits in FXS (Zeidler et al., 2015), suggesting that it 
could also be used to better understand the biological mechanism(s) underlying FXS vocalization 
deficits.  Unfortunately there have only been a few studies examining FXS mouse vocalizations 
and most have characterized abnormalities that either only exist at one developmental time point 
or do not correlate with abnormalities observed in FXS patients, questioning the 
neuroethological relevance towards FXS vocalization abnormalities (Lubs et al., 1984; Opitz and 
Sutherland, 1984; Rhoads, 1984; Borghgraef et al., 1987; Vilkman et al., 1988; Van Borsel et al., 
2008). To induce vocalizations most FXS studies have examined pup ultrasonic vocalizations 
(USV) due to maternal separation.  These studies have demonstrated that postnatal day (PND) 7 
FXS mice exhibit an increase in the number of frequency jump USVs compared to controls.  
However this increase was transient and found to return to control levels by PND 8-10 (Roy et 
al., 2012; Lai et al., 2014).  Studies in adult mice have further demonstrated FXS mice produce 
fewer USVs during courtship than control mice (Rotschafer et al., 2012); however, this study had 
the added confound of recording when both male and female mice were present, making detailed 
mouse specific analyses of USVs properties difficult. 
66 
 
 Interestingly, as mentioned above, none of these studies observed vocalization deficits to 
the extent of those observed in FXS patients (Lubs et al., 1984; Opitz and Sutherland, 1984; 
Rhoads, 1984; Borghgraef et al., 1987; Vilkman et al., 1988; Van Borsel et al., 2008). Although 
these studies examined many USV properties such as number, duration, rate, mean frequency, 
and bandwidth (Rotschafer et al., 2012) a detailed investigation of USV spectral properties, 
particularly frequency modulated USVs that many believe are reminiscent of bird song 
vocalizations in their spectral complexity referred to as syllables (Arriaga and Jarvis, 2013), has 
not been conducted.  These syllables have complex patterns and frequency jumps that are 
organized into phrases and motifs.  Phrases are vocalizations consisting of multiple syllables, 
while motifs are repeated syllable patterns (Holy and Guo, 2005).  Due to the complexity of 
these vocalization patterns and spectral properties, it has been argued that syllable production 
provides a better assessment of rodent vocal communication, especially when examining models 
of neurological disorders (Zampieri et al., 2014).  Given that FXS vocal abnormalities are 
predominately observed in deficits with communication, a detailed analysis of USV syllable 
production and spectral properties in FXS mice would provide a better assessment of their 
neuroethological relevance towards understanding FXS vocalization abnormalities.  The current 
study conducted a detailed analysis of USV syllable production and spectral properties in adult 
FXS mice following courtship separation. 
Methods & Analysis 
 
Housing and Care of Animals   
 
Adult (2-3 month) male C57/B6 fmr1 knockout (FXS) (n=10) and wildtype (WT) (n=10) 
mice were used.  Mice from the same liter were housed together by gender in standard laboratory 
67 
 
conditions (12 hr-12 hr light/dark cycle with food and water provided ad libitum).  All mice had 
prior exposure to the opposite sex before testing.    
USV Recording 
 
There were 3 main stages in the social encounter used to elicit and record USVs: 
Habituation, Interaction and Removal.  The Habituation step consisted of introducing the male 
mouse to the testing chamber for 5 minutes to minimize stressors from a novel environment.  
The Interaction step involved introducing a randomly assigned receptive female mouse into the 
testing chamber.  The male and female were allowed to interact for up to one minute, or until the 
male mouse mounted the female.  If mounting occurred, the female was immediately removed.  
The final stage, Removal, occurred immediately upon removing the female from the testing 
chamber.  Male mice were left in the testing chamber without the female for 2 minutes before 
returning to their home cage.  USVs were only recorded during the Removal stage to ensure no 
female vocalizations were recorded. 
All social encounters and USV recordings were performed in a testing chamber 
(7”x11”x5”) placed inside a larger sound attenuating chamber. An ultrasonic microphone 
(UltraSoundGate CM16/CMPA, Avisoft Bioacoustics) with a relatively flat frequency response 
(< 3 dB variability) up to 130 kHz was suspended 2 inches above the top of the testing chamber.  
The acoustic signal from the microphone was digitized at 375 kHz, 16 bits (UltraSoundGate 
416H, Avisoft Bioacoustics) and saved as a wav file (Avisoft-RECORDER, Avisoft 








Each social encounter was video recorded for later offline assessment of courtship 
behavior.  The videos were hand scored for courtship behaviors (total time until first mount; time 
to first interaction; interaction occurrences and time; percent time interacting; duration of time 
not interacting; and percent time not interacting) (Rotschafer et al., 2012).   
USV Examination 
 
The audio recordings from the Removal stage were processed and analyzed for USVs 
using a custom MATLAB program written by Holy and Guo (2005). First, spectrograms were 
created with a 512 FFT-length and 50% frame overlap, then bandpass filtered to remove sounds 
below 25 kHz and above 110 kHz. Background noise was removed with an intensity threshold. 
Potential USV syllables were automatically identified and extracted based on mean frequency, 
spectral purity, and spectral discontinuity of neighboring spectrogram bins (see Holy 2005 for 
details).  Next, these extracted sounds were identified as a USV syllable if they had a minimum 
duration of 5 ms, a spectral purity of 0.25 (at least 25% of the power in a single frequency, 
consistent with the narrow-band whistle of USVs vs. the broad-band noise associated with 
movement), and a spectral discontinuity of less than one, indicating a frequency change within 
the range previously reported for USV syllables frequency modulation.  
Frequency and temporal acoustic parameters of each extracted USVs were automatically 
calculated. From the frequency contour, average peak frequency (the frequency which had the 
most power), mean frequency, maximum frequency, minimum frequency, frequency bandwidth, 
and the difference between the starting and ending frequencies were extracted.  Additionally, 
overall duration of each USV as well as the time between USVs was calculated.  Bout analysis 
was conducted utilizing the time between USVs. Bouts were defined as a series of calls separated 
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by a 4 standard deviation change from the mean time between WT USVs, resulting in a value of 
~ 1 second.   
Additionally, Holy et al. have shown that male USVs in response to female separation 
exhibit a song-like characteristic (Fig. 4.1) that can be classified into three defined syllables (h, 
d, & u) based on an abrupt jumps between low (35-50 kHz) and high (70-90 kHz) frequencies.  
The syllable “h” is a jump to a high frequency, “d” is a downward jump to a low frequency, and 
“u” is an upward jump from a low frequency (Holy and Guo, 2005).  Note, the MATLAB code 
for isolating and classifying USVs into these three defined syllables and the subsequent syllable 
analyses are provided in Holy et al. (2005).  A single USV could be comprised of a single 
syllable or of multiple syllables (phrase).  Syllables that ended and began within 30 ms of each 
other were considered to be part of a single phrase (Fig. 4.1c).  Those USVs that did not meet the 
classification for a pre-determined syllable (referred to as “remainder” by Holy) were further 
classified based upon Zampieri et al (2014) into one of the following (Fig. 4.1a): short (<10 ms), 
flat (<5kHz modulation), upswing (increasing in frequency over the course of the USV), 
downswing (decreasing in frequency over the course of the USV), chevron/hill (a frequency 
increase then decrease in a symmetrical pattern with a starting and ending frequency within 5 
kHz), U (a frequency decrease then increase in a symmetrical pattern with a starting and ending 






Figure 4.1. Spectrogram representations of analyzed USVs. a. Representative SS calls [1 = short 
(<10 ms); 2 = flat (<5kHz modulation); 3 = upswing (increasing in frequency over the course of 
the USV); 4 = downswing (decreasing in frequency over the course of the USV); 5 = 
hill/chevron (a frequency increase then decrease in a symmetrical pattern with a starting and 
ending frequency within 5 kHz); 6 = U (a frequency decrease then increase in a symmetrical 
pattern with a starting and ending frequency within 5 kHz); & 7 = unclassified]. b. 
Representative Syllable calls [based on an abrupt jumps between low (35-50 kHz) and high (70-
90 kHz) frequencies “d” = (a downward jump to a low frequency); “h” = (a jump to a high 
frequency); & “u” = (an upward jump from a low frequency). c. Representative Phrase.  Phrases 
= vocalizations consisting of multiple syllables. 
Statistical Analyses 
 
All data collection and analyses were conducted using a blind procedure to eliminate 
experimenter bias. Statistical analyses were conducted using a mixed model ANOVA on SAS 
(http://www.sas.com/en_us/home.html) with genotype as a between subject factor and call 





During the interaction phase, the courtship was recorded to explore any genotype specific 
differences in male/female interaction.  There was no significant differences between FXS and 
WT mice in the total time to first mount, time to first interaction or number of interaction 
instances (Fig. 4.2a & 4.2c).  However, the total time spent interacting [Fig. 4.2a Interaction 
(F(1,11)=6.94;p<0.05)] and percent time interacting [Fig. 4.2b Interaction (F(1,11)=9.63;p<0.05)] 
was significantly higher in FXS. Subsequently WT mice spent significantly more time not 
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interacting [Fig. 4.2a No Contact (F(1,11)=9.52;p<0.05) & Fig. 4.2b No Contact 
(F(1,11)=9.63;p<0.05)].  Note, percent time was assessed to normalize the specific behavior to the 
total amount of time each male mouse had with a female as this varied depending upon the time 
until first mount, when the female was removed.   
 
 
Figure 4.2. Fragile X male mice spend significantly more time interacting with the female mice. 
a. Raw time distribution of total time of courtship (Time to First Mount), time to first interaction 
(Time to First Interaction), amount of time the male mouse spent interacting with the female 
mouse (Interaction) and amount of time spent not interacting (No Interaction).  FXS male mice 
spent significantly more time interacting with the females, and conversely, WT male mice spent 
significantly more time not interacting. b. The amount of time spent interacting or not interacting 
normalized to the total testing time [(Percent time = time spent interacting or not interacting / 
time to first mount) *100].  FXS male mice spent significantly more time interacting compared 
to their WT counterparts who spent significantly more time not interacting with the female. c. 
FXS male mice did not significantly differ in the number of times it interacted with the female 
(Interaction Instances). *<0.05 
USV Characterization 
 
Two WT mice, and three FXS mice were removed from the study for not producing 
vocalizations.  FXS male mice did not exhibit any significant differences in the number of USVs 
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or in the frequency and temporal acoustic parameters (Fig. A1-4).  Prior studies have 
demonstrated that FXS mice exhibit significantly fewer USVs in distinct bouts (Lai et al., 2014).  
In this study a bout was defined as “age-dependent minimum values in the distribution of the 
natural log of the [intercall interval]” (Lai et al., 2014).  In our study we were unable to 
reliability define a bout using this criteria.  Thus in an attempt to replicate these findings, a bout 
was defined as a series of calls being separated by a 4 standard deviation change from the mean 
time between WT USVs; however, no significant difference in the number of USVs per bout 
were detected (Fig. A5-6). Note there was also no significant difference in the mean time 
between USVs in FXS mice (Fig. A7-9). 
Three FXS mice vocalized but did not exhibit syllables and thus were moved from the 
syllable analysis.  Upon examination of the syllables, FXS mice were found to produce 
significantly more “u”s [Fig. 4.3c All “u” (F(1,10)=7.85;p<0.05)]  and more overall syllables 
which contained “u”s [Fig. 4.3c All USVs containing “u” (F(1,10)=9.72;p<0.05)] compared to WT 
mice. FXS mice also exhibited significantly fewer isolated “h” syllables [Fig. 4.3b Isolated h 
(F(1,10)=8.61;p<0.05)].  Upon examination of the spectral properties for each syllable it was 
determined that there were no differences in bandwidth or length for isolated “d” or “u” 
syllables; however, isolated “h” syllables were longer and had a greater bandwidth in FXS mice 
[Fig. 4.3e “h” Length (F(1,10)=17.73;p<0.05)  & Fig. 4.3h. “h” Bandwidth (F(1,10)=6.13;p<0.05) ].  
Furthermore, there were no significant differences in the average peak, mean, or max frequencies 
for “d” and “u” syllables; however, FXS mice had a significantly higher average max frequency 





Figure 4.3.  Occurrence rate and spectral properties for syllable production in Fragile X mice.  a. 
Occurrence rate of “d” to total syllable production (isolated “d” = individual syllable; All “d” = 
all instances of syllable; All USV containing “d” = all USVs that contain syllable).  b. 
Occurrence rate of “h” to total syllable production (see above for description of figure labeling). 
WT mice expressed more isolated “h” USVs compared to FXS mice and had a trend in 
expressing more “h” syllables in all calls.  c. Occurrence rate of “u” to total syllable production 
(see above for description of figure labeling).  FXS mice expressed more “u” syllables in all 
calls, utilized more “u”s in their calls, and had a trend to produce more isolated “u”s.  d. Duration 
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Figure 4.3 (cont.): of isolated “d” syllables.  e. Duration of isolated “h” syllables.  FXS mice 
generated significantly longer isolated “h” syllables.  f. Duration of isolated “u” syllables.  g. 
Bandwidth (frequency range) of isolated “d” syllables.  h. Bandwidth (frequency range) of 
isolated “h” syllables.  FXS mice exhibited significantly larger frequency jumps with isolated 
“h” syllables.  i. Bandwidth (frequency range) of isolated “u” syllables.  j. General frequency 
properties of “d” syllables (average peak, mean, average max, and absolute max frequencies).  k. 
General frequency properties of “h” syllables (average peak, mean, average max, and absolute 
max frequencies).  FXS mice had significantly higher average max frequency and a trend 
towards a higher peak frequency with their “h” syllables.  l. General frequency properties of “u” 
syllables (average peak, mean, average max, and absolute max frequencies).  *<0.05 
Interestingly, in addition to these individual syllable differences, FXS mice also 
generated more phrases and they were longer compared to their WT counterparts [Fig. 4.4a 
Syllable/Phrase Length (F(1,10)=26.33;p<0.05) & Fig. 4.4b Percent of Phrases in USVs 
(F(1,10)=8.22;p<0.05)].  FXS mice produced more phrases compared to individual syllables and 
within those phrases FXS mice exhibited more motifs [Fig. 4.4c Percent Syllable USVs which 
are Phrases (F(1,10)=79.82;p<0.05) & Fig. 4.4d Percent Motifs in Phrases (F(1,10)=9.73;p<0.05)].  
This pattern of repeated vocalization is consistent with the repetitive, perseverative speech 





Figure 4.4. Fragile X mice exhibit more longer phrases than WT mice. a. The average number of 
syllables in USVs containing syllables.  FXS mice produced USVs with a significantly greater number of 
syllables.  b. The percent of phrases in all USVs.  FXS mice exhibited significantly more phrases 
compared to WT mice.  c. The percent of syllable USVs that are phrases.  FXS mice had 
significantly more syllable USVs phrases.  d. Motif occurrence in phrases.  FXS mice had 
significantly more motifs in their phrases compare to their WT counterparts.  *<0.05 
A summary of the percent break down of each of these types can be found in Table 1.  
Finally, there were no significant differences observed in any of the SS USVs properties, except 
for the overall bandwidth in the Hill/Chevron calls, in which WT mice had significantly larger 







  WT FXS 
SS Short (1) 41.7 ± 5.73 40.9 ± 6.58 
SS Flat (2) 3.6 ± 0.52 3.9 ± 0.42 
SS Upswing (3) 5.4 ± 2.08 6.7 ± 0.90 
SS Downswing (4) 0.4 ± 0.36 1.3 ± 0.81 
SS Chevron/Hill (5) 0.2 ± 0.10 0.5 ± 0.34 
SS U (6) 0.2 ± 0.09 0.1 ± 0.07 
SS Unclassified (7) 33.9 ± 4.46 34.9 ± 3.61 
h 13.9 ± 2.39 7.3 ± 3.13 
d 0.2 ± 0.08 1.5 ± 1.48 
u 0.1 ± 0.04 0.4 ± 0.38 
Phrases 0.4 ± 0.31 2.2 ± 1.05 * 
Table 4.1. Distribution of all USV classifications (average +/- SEM).  No significant differences 
were seen in production of each classification between WT and FXS mice except for phrases.  
FXS male mice produced significantly more phrases than WT mice. *<0.05 
Discussion 
 
The current study demonstrated that adult FXS mice exhibit syllable vocalization 
abnormalities (longer phrases and more motifs) that are consistent with those observed in FXS 
patients (repetitive and perseverative speech), suggesting that FXS mice can be used to examine 
the underlying biological mechanism(s) and assess therapeutic interventions for FXS 
vocalization abnormalities.  Although the syndrome is associated with many abnormalities, a 
prominent characteristic in fragile X patients that can dramatically affect learning and cognition 
are speech vocalization abnormalities (repetitive, cluttered and perseverative speech patterns) 
(Herbst, 1980; Ferrier et al., 1991; Belser and Sudhalter, 2001; Cornish et al., 2004).  Until now 
FXS vocalization studies have been unable to characterize abnormalities that are consistent with 
those observed in FXS patients, thus hindering examination of the underlying cause for FXS 
vocalization deficits.   
Consistent with human FXS studies demonstrating repetitive, perseverative speech 
patterns, our studies demonstrated that FXS mice exhibited increased number of repeated-
syllable motifs.  Interestingly, this increase was not consistent across all syllables.  FXS mice 
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exhibited more “u” syllables, while WT mice exhibited more “h” syllables.  The overall use of 
“u” in all syllables and phrases was significantly higher in FXS mice.  This was noted by the 
increased number of USVs that contained “u” as well as an increased presence of “u” in phrases.  
It was also observed that FXS mice generated more isolated “u” syllables than WT, but not 
enough to reach significance.  WT mice, on the other hand, generated more “h” syllables, as they 
vocalized significantly more isolated “h” syllables than FXS mice.  There was also a tendency 
for WT mice to have more “h” syllables in their phrases, but this did not reach statistical 
significance.  Studies have suggested that calls spanning 50 kHz (a major frequency component 
of syllables) results in a positive rewarding state in rodents (Burgdorf et al., 2011), suggesting 
that these syllables have a behavioral and biological significance.  Unfortunately the behavioral 
and biological implications of vocalizing more of one syllable vs another, along with its 
relevance towards the human condition, is currently unknown.  However, these studies 
demonstrate that FXS mice exhibit syllable vocalization abnormalities consistent with those 
observed in FXS patients, indicating that they may be a viable model for studying repetitive 
vocalization abnormalities in FXS. 
Consistent with human FXS studies demonstrating repetitive, perseverative speech 
patterns, our studies demonstrated that FXS mice exhibited increased number of repeated-
syllable motifs.  Interestingly, this increase was not consistent across all syllables.  FXS mice 
exhibited more “u” syllables, while WT mice exhibited more “h” syllables.  The overall use of 
“u” in all syllables and phrases was significantly higher in FXS mice.  This was noted by the 
increased number of USVs that contained “u” as well as an increased presence of “u” in phrases.  
It was also observed that FXS mice generated more isolated “u” syllables than WT, but not 
enough to reach significance.  WT mice, on the other hand, generated more “h” syllables, as they 
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vocalized significantly more isolated “h” syllables than FXS mice.  There was also a tendency 
for WT mice to have more “h” syllables in their phrases, but this did not reach statistical 
significance.  Studies have suggested that calls spanning 50 kHz (a major frequency component 
of syllables) results in a positive rewarding state in rodents (Burgdorf et al., 2011), suggesting 
that these syllables have a behavioral and biological significance.  Unfortunately the behavioral 
and biological implications of vocalizing more of one syllable vs another, along with its 
relevance towards the human condition, is currently unknown.  However, these studies 
demonstrate that FXS mice exhibit syllable vocalization abnormalities consistent with those 
observed in FXS patients, indicating that they may be a viable model for studying repetitive 
vocalization abnormalities in FXS. 
Although the neuroanatomical brain regions/mechanism mediating rodent vocalization 
patterns are not fully understood, imaging and tracing studies have begun to delineate some 
critical brain regions and neuronal pathways.  Vocalizing in mice and not auditory stimulation 
has been shown to increase immediate early gene activation in primary motor cortex, premotor 
cortex, anterior cingulate cortex and anterodorsal striatum (Arriaga et al., 2012).  Tracing studies 
have further demonstrated projections from the cricothyroid and laryngeal muscles to the 
vocalizing-activated region in primary motor cortex.  Subsequent tracing analyses demonstrated 
that this region of primary motor cortex also projects directly to the brainstem nucleus ambiguus 
(Arriaga et al., 2012).  In mammals the brainstem nucleus ambiguus directly innervates the 
larynx and when lesioned abolishes the animals ability to vocalize (Kirzinger and Jurgens, 1985; 
Jurgens, 1998; Floody and DeBold, 2004; Jurgens and Ehrenreich, 2007).  For a detailed 
discussion of mouse vocalization patterns, neuroanatomical connections and possible homology 
to vocalization regions in song birds and humans see (Arriaga and Jarvis, 2013). 
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Although studies have not specifically examined FXS neuronal abnormalities in response 
to vocalization properties in the motor cortical, limbic, and striatal regions mentioned above, 
studies have characterized some FXS abnormalities in these brain regions that could contribute 
towards abnormal vocalization patterns.  At a gross anatomical level, the caudate has been shown 
to be enlarged in FXS (Gothelf et al., 2008; Hallahan et al., 2011; Hazlett et al., 2012), 
suggesting underlying neuronal abnormalities.  Likewise, the primary motor cortex, consistent 
with other brain regions previously studied (Irwin et al., 2002; Galvez and Greenough, 2005), 
has been shown to exhibit increased dendritic spine proliferation and elimination (Padmashri et 
al., 2013).  Furthermore, FXS mice exhibit disrupted learning-induced changes in LTP in the 
motor cortex (Padmashri et al., 2013) and impaired pre-synaptic LTP in anterior cingulate cortex 
(Koga et al., 2015). Although it is difficult to speculate how these abnormalities can result in the 
observed FXS repetitive vocalization, these studies demonstrate that brain regions known to 
mediate rodent vocalizations exhibit many neuronal and biochemical abnormalities in FXS.  In 
further support of a role for FMRP in proper vocal production the avian ortholog to FMRP 
(TGuFmr1) has been shown to be upregulated in prominent song nuclei of the male zebra finch 
brain immediately prior to song learning (Winograd et al., 2008).  These studies collectively 
suggest that FMRP plays a critical role in vocalization and when absent, results in various 
abnormalities that could disrupt that process resulting in the observed FXS syllable 
abnormalities. 
Although this study is the first to examine syllable production in FXS mice, prior studies 
have looked at other vocalization properties.  For example, studies utilizing maternal separation 
to generate vocalizations have demonstrated that USV production rate was significantly 
increased in FXS mice; however, this was shown to only occur at PND 7 (Lai et al., 2014).  
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Contrary to these findings, Rotschafer et al., (2012) demonstrated that FXS mice exhibit a 
reduced vocalization rate during courtship compared to WT mice.  Interestingly, it has recently 
been shown that both males and females undergo interaction-induced USVs during courtship 
behavior (Neunuebel et al., 2015).  Thus, it is difficult to determine if the reduced vocalization 
rate from Rotschafer et al., (2012) is due to FXS vocalization abnormalities, differences in 
interaction-induced female vocalizations or a combination of both.  In support of there being 
differences in the courtship behavior, our study demonstrated that FXS mice spent significantly 
more time interacting with the female than controls (Fig. 4.2).  Unfortunately we are unable to 
determine if this is due to FXS increased hyperactivity (Bakker et al., 1994) or a consequence of 
not being able to properly communicate. To control for possible differences during courtship 
altering vocalization patterns, USVs were only examined after the female was removed. 
Interestingly, after removing the female we did not detect a significant difference in the 
vocalization rate in FXS mice (Fig. A11), suggesting that the decreased vocalization rate 
observed in Rotschafer et al was due to abnormalities in communication and not an inability to 
vocalize.  Furthermore, these findings, along with prior studies suggesting that mouse syllable 
vocalizations have a behavioral significance (Burgdorf et al., 2011), suggest that our observed 
repetitive syllable production in FXS hinders effective communication and is an underlying 
cause for FXS decreased vocalization during courtship (Rotschafer et al., 2012). 
Abnormalities in vocalization production are a prevalent disorder that exists in various 
types of ASD including FXS.  Difficulties in speech production can often have dramatic effects 
on both social and cognitive development.  Although many mouse models of ASD have 
demonstrated vocalization abnormalities such as decreased USVs production, FXS mice have not 
reliably been shown to exhibit vocalization abnormalities that are consistent with those observed 
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in FXS patients such as repetitive, cluttered and perseverative speech patterns (Borghgraef et al., 
1987; Jamain et al., 2008; Radyushkin et al., 2009; Gaub et al., 2010; Kurz et al., 2010; Wohr et 
al., 2011). The current study demonstrated that adult FXS mice exhibit a repetitive USV syllable 
production that is consistent with that observed in FXS patients. These findings further 
strengthen the neuroethological relevance of FXS mice and suggest that examination of 
perseverative syllable production can be used in future analyses of FXS mice vocalization 
abnormalities.  Furthermore, the current study provides a means for future investigations into the 





CHAPTER 5: BLOCKING ELEVATED VEGF-A ALTERS A MYRIAD OF  
 




 Fragile X Syndrome (FXS) is the most common form of single gene inherited mental 
retardation.  We have recently demonstrated that Vascular Endothelial Growth Factor  A (VEGF-
A) is not only elevated in FXS mice, but its modulation can lead to molecular and behavioral 
rescue of some FXS abnormalities (Belagodu et al., 2017).  These findings suggest that VEGF-A 
modulation can be used to alleviate FXS abnormalities.  This study set out to determine the 
extent in which blocking VEGF–A can alleviate many well established behavioral FXS 
phenotypes such as locomotor activity, anxiety-like behavior, stereotypy, and USV deficits.  The 
current study found, consistent with those from other studies, that FXS mice exhibit increased 
locomotor activity and hyperactivity, reduced anxiety-like behavior, increased stereotypy, and 
increased production of phrases and motifs in USV profiles.  Interestingly, blocking VEGF-A 
with Bevacizumab was found to not alleviate any of these deficits. Although these findings are 
disappointing, they are not surprising given our prior analyses of hyperactivity following 
Bevacizumab treatment, in which the increased hyperactivity in FXS was unaltered with 
Bevacizumab treatment.  Many of the measures of anxiety-like behavior and stereotypy can be 
influenced/driven by hyperactivity and thus would be unaltered with this type of intervention.  
Interestingly, blocking VEGF-A did not have a drug treatment effect on USV production profiles 
(Belagodu et al., 2016).  Rather much to our surprise both Saline and Bevacizumab alleviated 
FXS USV abnormalities.  These findings suggest that this vocalization deficit could be altered 
through handling and warrants further exploration into the neuronal mechanism mediating USV 
production in mice.  Overall, these findings, along with our prior studies, demonstrate that 
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blocking VEGF-A has beneficial effects on specific FXS abnormalities, and that further 
exploration into the specific types of behaviors that can be alleviated along with optimization of 
drug dosage will be needed. 
Introduction 
 
 Fragile X Syndrome (FXS) is the leading cause of inherited genetic autism spectrum 
disorder with higher incidence rates in males (1:3600) than females (1:8000) (Cornish et al., 
2008).  The transcriptional silencing of FMR1, the gene which encodes the Fragile X Mental 
Retardation Protein (FMRP) is known to be the primary cause of FXS (Pieretti et al., 1991; 
Verkerk et al., 1991); however, its exact mode of action in mediating behavioral and anatomical 
abnormalities are not well understood.  A prevailing theory on changes induced by the lack of 
FMRP is the unregulated activation of metabotropic glutamate receptor (mGluR) downstream 
components, such as the mammalian target of rapamycin (mTORC1) (Bear et al., 2004; Sharma 
et al., 2010; Hoeffer et al., 2012).  mTORC1 plays a critical role in regulating levels of numerous 
downstream proteins.  One of these proteins of interest is vascular endothelial growth factor A 
(VEGF-A).  We have previously shown that VEGF-A, under the regulation of mTORC1, 
exhibits elevated brain expression in FXS (Belagodu et al., 2017).   
VEGF-A has historically been classified as a prominent regulator of vascular growth with 
increased expression being synonymous with increased vasculature (Neufeld et al., 1999).  
Consistent with these findings FXS patients have been shown to exhibit blood profusion 
abnormalities (Balci et al., 2006; Kabakus et al., 2006) and our findings have shown that adult 
FXS mice have increased vasculature (Galvan and Galvez, 2012).  Interestingly, in addition to 
modulating vasculature, recent studies have demonstrated that VEGF-A can alter many neuronal 
properties. Treatment with VEGF-A has yielded neuroprotective properties, by increasing overall 
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survival rates of nerve cells in the CNS and Schwann cells in the PNS (Sondell et al., 1999), as 
well as increasing neurogenesis in the dentate gyrus (Jin et al., 2002).  This is mirrored in FXS, 
with increased proliferation rate of sertoli cells (Hagerman and Hagerman, 2003) and BrdU 
positive cells in the dentate gyrus of the hippocampus (Jin et al., 2002).  Furthermore, VEGF 
stimulation has led to axonal outgrowth and increased neurite outgrowth and branching (Jin et 
al., 2006) with one of its receptors (VEGFR2) being found on axonal growth cones (Sondell et 
al., 1999; Sondell et al., 2000) and dendritic synapses (De Rossi et al., 2016).  Interestingly, the 
FXS Drosophila model exhibits excessive axonal growth in length and arborization complexity 
(Pan et al., 2004).  Furthermore, FXS has been shown to result in increased number of dendritic 
spines due to excessive spine proliferation and turn over (Pan et al., 2010).  This collectively 
suggests that VEGF-A plays a critical role in neuronal properties, and could potentially be a 
venue for alleviating FXS neuronal abnormalities. 
 To better understand the potential role for VEGF-A in mediating FXS abnormalities, our 
subsequent studies explored the beneficial effects of blocking VEGF-A binding to its receptor.  
Using the anti-cancer medication Bevacizumab (Genentech), a humanized monoclonal antibody 
(Lu et al., 2012; Walker et al., 2012), we were able to reduce VEGF-A levels in FXS brain to 
those observed in control mice (Belagodu et al., 2017).  More importantly, this same drug 
treatment alleviated FXS macroorchidism and reduced Synapsin-1 brain expression, a marker for 
synapse density (Sudhof et al., 1989; Cesca et al., 2010), to control levels.  To explore the 
beneficial behavioral effects of blocking VEGF-A, Bevacizumab treated mice were then assessed 
on Novel Object Recognition.  Novel Object Recognition is a cognitive learning task that has 
been shown to be sensitive to FXS, resulting in impaired performance.  Our behavioral analyses 
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demonstrated that blocking VEGF-A binding to its receptor was able to alleviate the FXS 
cognitive impairment observed with Novel Object Recognition.   
 These initial studies exploring the effects of blocking VEGF-A binding on FXS 
behavioral abnormalities have been very promising; however, the full implications of VEGF-A 
modulation on FXS abnormalities are still unknown.  The following study set out to assess the 
effect of blocking VEGF-A on various behavioral abnormalities commonly associated with FXS.  
Specifically, the follow study set out to examine measures of anxiety (Hagerman and Hagerman, 
2003; Cordeiro et al., 2011; Bailey et al., 2012), repetitive behaviors such as self-grooming 
(McNaughton et al., 2008; Pietropaolo et al., 2011) and marble bury (Spencer et al., 2011; 
Veeraragavan et al., 2012; Gholizadeh et al., 2014), and vocalization deficits (Rotschafer et al., 
2012).  We have recently shown that FXS mice exhibit ultrasonic vocalizations deficits 
consistent with abnormalities observed in patients (Belagodu et al., 2016).  Through such a wide 
spectrum analysis of the effects of VEGF-A modulation on FXS abnormalities, the following 
study will provide a better assessment of the potential benefits of VEGF-A modulation for 
therapeutic interventions. 
Methods & Analysis 
 
Housing and Care of Animals   
 
Adult (PND 60) male C57/B6 FMR1 knockout (FXS) and wildtype (WT) mice were 
used.  Mice were housed in standard laboratory conditions (12 hr-12 hr light/dark cycle with 
food and water provided ad libitum).  
Blocking VEGF-A 
 
Based upon our prior study exploring the beneficial effects of VEGF-A modulation on 
FXS abnormalities (Belagodu et al., 2017), FXS (n=30) and WT (n=39) mice were given 5 
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mg/kg Bevacizumab or Saline IP every other day for 10 days.   Prior to and following drug 
treatment various behavioral assessments outlined below were conducted. 
 
 
Figure 5.1: Schematic of injection scheme with time points (PND) for each behavioral 
assessment.  Note, anxiety assessments were conducted on PND 69 mice from our prior study 
(Belagodu et al., 2017), that were treated starting on PND 60 as outlined above but did not 
receive any pre-injection treatments. 
 
Open Field Assessment 
 
 To assess anxiety a modified Open Field assessment was used.  Upon placing the mouse 
into a novel cage for 10 min the time spent in the center (Center 50%), edges, corners, crossings 
into center area, and the amount of time immobile in each of the aforementioned areas were 
assessed via Anymaze (v4.98) (Ennaceur, 2014).  FXS mice have been observed to travel 
increased distances as well as spend more time mobile compared to their WT counterparts.  
Furthermore, FXS mice typically traverse a greater ratio of distance in the center region to total 
distance traveled compared to their WT counterparts, suggesting decreased anxiety-like behavior 
(Peier et al., 2000; Spencer et al., 2005).  
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Marble Bury Assessment  
 
 Marble Bury, a well-established paradigm of repetitive (stereotypy) behavior (Thomas et 
al., 2009), was used to explore the extent of benefits that Bevacizumab treatment can provide.  
This paradigm has been extensively used in studying repetitive behavior in autism models 
(Hoeffer et al., 2008; Jamain et al., 2008).  Furthermore, studies in FXS mice have shown 
increases in the number of marbles buried compared to their WT counterparts (Spencer et al., 
2011; Veeraragavan et al., 2012; Gholizadeh et al., 2014).  To assess this stereotypic behavior, a 
modified protocol from (Deacon, 2006) was used.  Briefly, mice were placed in a new cage 
consisting of 5 cm of woodchip bedding and 15 evenly spaced (at least 1 inch apart) glass 
marbles for 30 minutes.  The mice were then removed, and the number of marbles buried was 
assessed.  Marbles were considered fully buried if they were more than 50% covered.  The 
Marble Bury Assessment was conducted prior to injections with a follow up test following drug 
treatment to obtain a within subject assessment.   
USV Analysis 
All social encounters and USV recordings were performed in a testing chamber 
(7”x11”x5”) placed inside a larger sound attenuating chamber. An ultrasonic microphone 
(UltraSoundGate CM16/CMPA, Avisoft Bioacoustics) with a relatively flat frequency response 
(< 3 dB variability) up to 130 kHz was suspended 2 inches above the top of the testing chamber.  
The acoustic signal from the microphone was digitized at 375 kHz, 16 bits (UltraSoundGate 
416H, Avisoft Bioacoustics) and saved as a wav file (Avisoft-RECORDER, Avisoft 
Bioacoustics) for later analysis. 
All mice had prior exposure to the opposite sex.  Following drug treatment, there were 3 
main stages used to elicit and record USVs: Habituation, Interaction and Removal.  The 
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Habituation step consisted of introducing the male mouse to the testing chamber for 2 minutes to 
minimize stressors from the novel environment.  The Interaction step involved introducing a 
randomly assigned receptive female mouse into the testing chamber.  The male and female mice 
were allowed to interact for up to one minute, or until mounting of the female occurred.  The 
final stage, Removal, occurred immediately upon removing the female mouse from the testing 
chamber.  Male mice were left in the testing chamber without the female for 10 minutes before 
returning to their home cage.  USVs were only recorded during the Removal stage to ensure no 
female vocalizations were recorded. 
USV Examination 
 
 Audio recordings from the Removal stage were processed and analyzed for USVs using 
the previously described custom MATLAB program (Belagodu et al., 2016).  Spectrograms were 
created with a 512 FFT-length and 50% frame overlap, then bandpass filtered to remove sounds 
below 25 kHz and above 110 kHz. Background noise was then removed with an intensity 
threshold. Potential USV syllables were automatically identified and extracted based on mean 
frequency, spectral purity, and spectral discontinuity of neighboring spectrogram bins.  These 
extracted USVs were identified as a syllable/phrase if they had a minimum duration of 5 ms, a 
spectral purity of 0.25 (at least 25% of the power in a single frequency, consistent with the 
narrow-band whistle of USVs vs. the broad-band noise associated with movement), and a 
spectral discontinuity of less than one, indicating a frequency change within the range previously 
reported for USV syllable frequency modulation.  Those USVs that did not meet the 
classification for a pre-determined syllable referred to as “remainder” (Holy and Guo, 2005) 
were lumped into a miscellaneous category as our previous analysis showed no significant 
differences in any of the other mentioned categories previously listed (Belagodu et al., 2016).    
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Statistical Analysis  
 
All data collection and analyses were conducted using a blind procedure to eliminate 
experimenter bias. Statistical analyses were conducted using a mixed model ANOVA on SAS 
(http://www.sas.com/en_us/home.html) with genotype as a between subject factor and behavioral 
assessments prior to and following drug treatments as within subject factors.  For USV analyses 
the time between calls or percent of a certain type of call were also treated as within subject 
factors.   
Results 
Open Field Assessment 
 
 FXS and WT mice were assessed for general locomotor activity and anxiety-like 
behavior via an Open Field Paradigm.  Consistent with previous studies (Peier et al., 2000; 
Spencer et al., 2005), FXS mice were found to exhibit increased distance traveled [Fig. 5.2a; 
F(1,28)=9.26; p<0.005], average velocity [Fig. 5.2b; F(1,28)=9.54; p<0.005], percent time mobile 
[Fig. 5.2c; F(1,28)=9.82; p<0.005] and immobile [Fig. 5.2e; F(1,28)=9.83; p<0.005], and bouts of 
mobility [Fig. 5.2d; F(1,28)=4.91; p<0.005] and immobility [Fig. 5.2f; F(1,28)=4.89; p<0.005].  FXS 
mice display increased distance traveled, velocity, and percent time mobile which are all 
indicative metrics of hyperactivity.  FXS mice also had lower mobility bouts, but traveled a 
greater distance at a higher speed, suggesting that each instance of mobility consisted of greater 
locomotion than their WT counterparts.  Furthermore, the aforementioned measures of increased 
motion suggested reduced anxiety and increased exploratory behavior.  To further support this, 
FXS mice also spent a decreased amount of time immobile, with decreased bouts of immobility 
than their WT counterparts.  Addressing stereotypy behavior from the Open Field Paradigm, 
90 
 
FXS had an increased amount of rotations [Fig. 5.2g; F(1,26)=6.08; p<0.005], an indication of 


















































Figure 5.2 (cont.). Open Field Assessment metrics for locomotion (a.-d.), anxiety-like (c.-f.), and 
stereotypy behavior (g.) comparing WT vs FXS mice treated with Bevacizumab or Saline.  
Treatment yielded no effect in all metrics for either group.  a. Total distance traversed in the 
training chamber.  FXS mice had significantly more movement than WT mice.  b. Average 
velocity of movement during the habituation stage.  FXS mice had significantly faster movement 
than WT mice.  c. Percent time in which the mice were mobile during the habituation stage.  
FXS mice were mobile for a significantly greater amount of time than WT mice.  d. Mobility 
bouts during the habituation stage.  FXS mice had significantly fewer instances where they 
began moving from rest than WT mice.  e. Percent time in which the mice were immobile during 
the habituation stage.  FXS mice were immobile for a significantly shorter amount of time than 
WT mice.  f. Immobility bouts during the habituation stage.  FXS mice had significantly fewer 
number of instances when they were immobile than WT mice.  g. Total rotations of the mouse 
during the habituation stage.  FXS mice rotated significantly more than WT mice.  Bevacizumab 
= Bev. *<0.05.   
 
Interestingly, anxiety-like behavioral effects in FXS mice were more pronounced in the 
first two minutes of the Open Field Paradigm, particularly with a decrease in the number of 
crossings into the center region [Fig. 5.3a; F(1,59)=4.91; p<0.005], time spent in the center region 
[Fig. 5.3b; F(1,59)=6.61; p<0.005], distance traveled in the center region [Fig. 5.3a; F(1,59)=4.56; 
p<0.005], and finally the maximum instance in the center region [Fig. 5.3a; F(1,59)=5.73; 
p<0.005].  A decrease in these metrics are indicative of increased exploratory behavior and 
reduced anxiety in mice (Peier et al., 2000; Spencer et al., 2005).  Ultimately, there were no 
significant effects of Bevacizumab treatment on any of the aforementioned behavioral measures, 
suggesting that blocking VEGF-A does not alter hyperactivity or anxiety levels in FXS mice 
during the entire paradigm or during the initial two minutes in which the measures were more 





Figure 5.3. Open Field Assessment Center Region metrics for anxiety-like behavior per minute 
for the first two minutes of the paradigm comparing WT vs FXS mice treated with Bevacizumab 
or Saline.  Treatment yielded no effect in any metrics for either group.  a. Crossings to/from the 
center region.  FXS mice had significantly fewer crossings to the center region compared to WT 
mice.  b. Time in which the mice were mobile in the center region.  FXS mice were mobile in the 
center region for a significantly shorter amount of time than WT mice.  c. Total distance 
traversed in the center region.  FXS mice had significantly less movement in the center region 
than WT mice.  d. Maximum length of a bout spent in the center region.  FXS mice maximum 
time moving in the center region was significantly lower than WT mice.  Bevacizumab = Bev. 
*<0.05.   
 
Marble Bury Assessment 
 
 Stereotypy behavior was further assess via Marble Bury, a prevailing phenotype in 
autism rodent models (Hoeffer et al., 2008; Jamain et al., 2008).  Consistent with previous 
studies, FXS mice exhibited significantly increased burrowing behavior, resulting in an increased 
percentage (%) of marbles buried [Fig. 5.4; F(2,80)=2.79; p<0.005] (Spencer et al., 2011; 
Veeraragavan et al., 2012; Gholizadeh et al., 2014).  Unfortunately, Bevacizumab treatment did 
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not alleviate this difference in FXS mice.  Interestingly, post-hoc analyses of post treatment 
groups (FXS/WT Saline/Bevacizumab) failed to detect a significant difference between groups 
[Fig. 5.4; F(2,80)=1.63; p=0.2021].  These findings suggest that ten days of interacting with and 
treating FXS mice (Saline or Bevacizumab) impaired detection of the Marble Burying deficit.  
This is further discussed in the proceeding discussion below. 
 
 
Figure 5.4. Marble burying behavior was not altered with 10 days of Bevacizumab treatment.  
FXS mice naturally bury more marbles than WT mice; however, Bevacizumab did not 




 Examination of courtship induced vocalizations with Bevacizumab treatment yielded 
intriguing results.  Our previous study demonstrated that sexually naïve FXS mice exhibited 
more syllables (frequency modulated vocalizations) (Holy and Guo, 2005) and a higher 
incidence of these syllables in phrases (vocalizations containing multiple syllables) (Belagodu et 
al., 2016).  Consistent with these findings, the pre-treatment analyses demonstrated that FXS 
sexually experienced mice exhibited significantly increased percentage of syllables [Fig. 5.5a; 
F(1,21)=5.63; p<0.005] and phrases [Fig. 5.5b; F(2,40)=3.42; p<0.005].  FXS mice also exhibited a 
trend to produce longer phrases with more syllable units [Fig. 5.5c; F(2,40)=3.41; p<0.005] and an 
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Figure 5.5. Treatment with Bevacizumab did not selectively alleviate pre-treated FXS mouse 
syllable and phrase vocalizations deficits.  a. Percent of syllables in total vocalizations produced.  
Pretreated FXS mice produced more syllables than WT mice; however, Bevacizumab treatment 
had no effect, while posttreatment Saline FXS mice produced significantly fewer syllables than 
pretreated FXS mice.  b. Percent of phrases in total vocalizations produced.  Pretreated FXS mice 
produced more phrases than WT mice; however, Bevacizumab treatment had no effect, while 
posttreatment Saline FXS mice produced significantly fewer phrases than pretreated FXS mice.  
c. Average number of syllables in phrases.  Pretreated FXS had a trend for increased phrase 
length compared to their WT counterparts.  Treatment with either Bevacizumab or Saline had 
significantly reduced phrase length compared to pretreated FXS mice.  d. Motif occurrence in 
phrases.  Pretreated FXS mice had significantly more motifs in their phrases compared to their 
WT counterparts; however, there was no benefit from Bevacizumab treatment.  Bevacizumab = 




 Interestingly, treatment with either Saline or Bevacizumab, either significantly alleviated 
or had no effect on measured vocalization abnormalities in FXS mice. Specifically, FXS treated 
mice (Saline or Bevacizumab) exhibited a significant reduction to WT mouse levels in the 
percentage of syllables (difference seen only with Saline treatment) [Fig. 5.5a; F(1,14)=7.59; 
p<0.005], phrases (difference seen only with Saline treatment) [Fig. 5.5b; F(2,40)=3.42; p<0.005], 
length of syllable units in phrases [Fig. 5.5c; F(2,40)=3.41; p<0.005], and no effect in the 
percentage of motifs in phrases.  Interestingly, there were no significant differences in WT 
mouse vocalizations between pre- and post-treated USV profiles, suggesting that the change in 
vocalization patterns was specific to FXS mice.   
Discussion 
 
Blocking VEGF-A via Bevacizumab has been shown to have global effects on the brain; 
reducing Synapsin-1 levels in both the Visual Cortex and CA1 of the Hippocampus.  These 
findings along with its ability to alleviate novel object recognition deficits (Belagodu et al., 
2017), suggest that targeting the VEGF-A pathway could be a viable treatment option for a 
myriad of FXS behavioral phenotypes.  The current study explored the extent of this 
intervention’s ability (blocking VEGF-A with Bevacizumab) to alleviate various common FXS 
behavioral abnormalities.  FXS mice typically exhibit increased locomotor activity coupled with 
decreased anxiety-like behaviors such as increased crossing and exploration with less time spent 
in the training chamber center region (Bakker et al., 1994; Peier et al., 2000; Spencer et al., 
2005).  Consistent with these studies, our analyses demonstrated that FXS Saline treated mice 
exhibited increased locomotion, stereotypy, along with decreased anxiety-like behavior, and 
altered USV production profiles with increased percentage of syllables, phrases and motifs (Peier 
et al., 2000; Spencer et al., 2005; Veeraragavan et al., 2012; Gholizadeh et al., 2014; Belagodu et 
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al., 2016).  Interestingly, Bevacizumab treatment did not significantly alter anxiety-like behavior 
in FXS mice.  This could be attested to a lack of Bevacizumab treatment on alleviating FXS 
hyperactivity (Belagodu et al., 2017), as increased FXS locomotor activity would increase 
overall exploratory behavior.  Thus, further suggesting that any FXS behavior driven by 
increased activity levels would not be alleviated though blocking of VEGF-A. 
In addition to the observed increased activity levels, stereotypy behavior is commonly 
observed in FXS mice with increased rotations (Dolan et al., 2013) and increased number of 
marbles buried in the Marble Bury Assessment (Spencer et al., 2005; Veeraragavan et al., 2012; 
Gholizadeh et al., 2014).  Consistent with prior studies, our analyses demonstrated that FXS 
Saline treated mice rotated more and buried more marbles than their WT counter parts.  
However, Bevacizumab treated did not significantly change either metric of stereotypy.  This 
could again be due to the inability of Bevacizumab to alleviate the hyperactivity deficit, which 
stereotypy behavior is heavily influenced by.  
 In addition to examination of hyperactivity/anxiety behaviors, the current study explored 
the effects of Bevacizumab in FXS on previously reported courtship induced vocalization 
deficits (Belagodu et al., 2016).  Consistent with our previous study, the current study found that 
pretreated FXS mice exhibited increased syllable and phrase production, coupled with increased 
presence of motifs compared to their WT counterparts.  Interestingly, both Saline and 
Bevacizumab treatment decreased the overall production of syllables, and subsequently phrases 
and motifs in FXS mice making them indistinguishable from WT mice.  Although the underlying 
cause for this is not known, it is possible that the initial vocalization event allowed FXS mice to 
fine tune their vocalizations, so they better resemble those observed in WT mice. To explore this 
potential possibility, pre-exposure assessments should be eliminated in subsequent analyses.  
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This would mirror the pretreatment mice in this study, and those tested in our previous study 
(Belagodu et al., 2016)  
The following study provided additional understanding of FXS mice vocalizations, ideal 
time points to assess differences in vocalizations, and potential causes for variations seen in 
published FXS vocalization studies.  Currently these findings are limited to syllables, phrases 
and motifs.  Further investigation of isolated syllables, particularly frequency components (max 
frequency and bandwidth of each isolated syllable) which were previously found to be 
significantly different (Belagodu et al., 2016) could be beneficial to obtain a more holistic 
understanding of potential beneficial effects of Bevacizumab on FXS vocalizations.  
Furthermore, our prior study showed that male FXS mice spend more time interacting with the 
female mouse (Belagodu et al., 2016).  Thus, an assessment of the pre- and post-treatment 
courtship behavior could provide insight into potential Bevacizumab induced changes in FXS 




CHAPTER 6: ASSESSING THE EFFECT OF BLOCKING VEGF RECEPTORS ON  
 




 Fragile X Syndrome is the most common form of inherited mental retardation.  Recent 
studies from our laboratory have demonstrated that Vascular Endothelial Growth Factor  A 
(VEGF-A) is elevated in FXS mice and when reduced can alleviate many molecular and 
behavioral FXS phenotypes (Belagodu et al., 2017).  However, VEGF-A is only one of five 
VEGF Family molecules which can bind to three VEGF Receptors.  To assess which of these 
receptors, and subsequent mechanisms are driving the molecular and behavioral rescues 
observed in the aforementioned study, mice were dosed with VEGF Receptor blockers and the 
same molecular and behavioral abnormalities examined.  Blocking VEGFR2 and VEGFR3 was 
found to significantly decrease Synapsin-1 expression in FXS mouse brain.  Interestingly, our 
subsequent behavioral assessments demonstrated that blocking the receptors (VEGFR1, 
VEGFR2, or VEGFR3) had not effect on hyperactivity or any of the behavioral measures that are 
influenced by hyperactivity (locomotor activity, anxiety-like behavior, and marble bury).  
Blocking VEGFR2 was found to reduce the number of rotations per minute in FXS mice, a 
measure of stereotypy.  These studies suggest that VEGFR2 is the primary driver through which 
VEGF-A mediates some FXS abnormalities; however, further exploration will be needed to 




Fragile X Syndrome (FXS) is the leading form of inherited mental retardation, primarily 
affecting males at twice the incidence rate than females (Cornish et al., 2008).  The primary 
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cause of FXS is the transcriptional silencing of FMR1, the gene that codes for the Fragile X 
Mental Retardation Protein (FMRP) (Pieretti et al., 1991; Verkerk et al., 1991).  Although the 
cause of FXS is known, the mechanism by which an absence of FMRP alters anatomical, and 
cognitive properties is not known. 
Previous studies from our laboratory have demonstrated that one mechanism mediating 
FXS abnormalities in adulthood is the abnormal expression of Vascular Endothelial Growth 
Factor A (VEGF-A) (Belagodu et al., 2017).  Our studies demonstrated that adult FXS mice 
exhibit elevated VEGF-A expression and blocking VEGF-A can alleviate many adult FXS 
abnormalities (Belagodu et al., 2017).  VEGF-A is the most prominent regulator of vascular 
growth (Neufeld et al., 1999) with proper expression being critical for normal vascular 
development and viability (Carmeliet et al., 1996; Ferrara et al., 1996).  Consistent with these 
findings, FXS patients and mice have been shown to exhibit abnormal cerebral blood profusion 
(Balci et al., 2006; Kabakus et al., 2006) and increased brain vasculature (Galvan and Galvez, 
2012), suggesting that increased VEGF-A is causing vascular abnormalities in FXS.   
Interestingly, in addition to vascular regulation, VEGF-A has been shown to alter many 
neuronal properties that are disrupted in FXS.  For example, increasing VEGF-A expression 
stimulates axonal growth, neurite outgrowth, and enhances cell survival (Silverman et al., 1999; 
Sondell et al., 1999; Sondell et al., 2000; Jin et al., 2002).  Consistent with these findings, FXS is 
also associated with increased axonal material, elevated dendritic spine density, and excessive 
cell proliferation (Pan et al., 2004; Galvez and Greenough, 2005; Pan et al., 2010); further 
suggesting that altered VEGF-A expression is an underlying cause for FXS abnormalities.  In 
support of this hypothesis our studies have shown that blocking VEGF-A binding to its receptor 
alleviates many FXS behavioral (Novel Object Recognition), physical (reduction in 
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macroorchidism), and molecular abnormalities (Synapsin-1 and VEGF-A levels) (Belagodu et 
al., 2017).   
Unfortunately, the mechanism by which VEGF-A is able to alleviate these FXS 
abnormalities is not known.  VEGF-A is known to bind to one of three VEGF receptors 
(VEGFR1, VEGFR2, and VEGFR3).  VEGFR1 plays a critical role in vascular development 
(Fong et al., 1995) and more interestingly, is found with increased expression of astrocytes, 
suggesting that it aids in astroglial expression of various growth factors (Krum et al., 2008; 
Koyama et al., 2014).  VEGFR2 is the primary driver of angiogenesis (Dvorak, 2002); however, 
there is growing evidence of increased functionality beyond blood vessel growth.  VEGFR2 has 
been found on axonal growth cones (Sondell et al., 1999), implicated in driving microvascular 
permeability (Dvorak, 2002), as well as endothelial cell proliferation and survival (Millauer et 
al., 1993; Zeng et al., 2001).  Furthermore, selective silencing of neuronal VEGFR2 has been 
indicated to impair hippocampal-dependent plasticity, memory consolidation, and learning (De 
Rossi et al., 2016), suggesting that it is vital in mediating learning mechanisms.  Finally, 
VEGFR3 has been suggested to play a critical role in the development and plasticity of vascular 
networks during embryogenesis and drive lymphangiogenesis later in development (Kukk et al., 
1996; Dumont et al., 1998; Paavonen et al., 2000; Alitalo and Carmeliet, 2002; Laakkonen et al., 
2007).  The current study used blockers for each of these receptors (MF-1; VEGFR1: DC101; 
VEGFR2: and mF4-31C1; VEGFR3) to determine the initial mechanism by which blocking 




Figure 6.1. Schematic of binding affinities of VEGF Family of molecules to their various VEGF 
Receptors. 
 
Methods & Analysis 
Housing and Care of Animals   
 
Adult (PND 60) male C57/B6 FMR1 knockout (FXS) and wildtype (WT) mice were 
used.  Mice were housed in standard laboratory conditions (12 hr-12 hr light/dark cycle with 
food and water provided ad libitum).  
Blocking VEGF Receptors 
 
 For initial analysis of the effects of receptor blocking on synapse density, receptor 
blocking doses of 25 and 50 mg/kg every other day for 10 days intraperitoneal (IP) were 
selected.  These doses were based upon prior studies exploring the blocker’s efficiency for 
altering vascular properties [MF-1 (VEGFR1) (Wang et al., 2004; Huang et al., 2011), DC101 
(VEGFR2) (Dias et al., 2001; De Bandt et al., 2003; Wang et al., 2004; Van de Veire et al., 
2010; Huang et al., 2011), or mF4-31C1 (VEGFR3) (Pytowski et al., 2005; Roberts et al., 2006; 
Laakkonen et al., 2007)].  Based upon this initial assessment, our subsequent behavioral analyses 
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were conducted with 50 mg/kg IP every other day for 10 days.  Note due to material transfer 
agreements with Eli Lilly only FXS mice were given the receptor blockers. 
 
 
Figure 6.2: Schematic of injection scheme with time points (PND) for each behavioral 




 To determine the effects of blocking VEGF Receptors on synapse density (determined 
via Synapsin-1 Expression), mice were given either MF-1, DC101, mF4-31C1, or Saline as 
outlined above.  Postmortem samples were then processed for Synapsin-I expression as 
previously described (Belagodu et al., 2017).  Briefly, following the last injection, mice [FXS 
(n=21) and WT (n=3)] were sacrificed and cortical hemispheres, including cortical white matter 
and hippocampus were dissected for Western Blot analysis.  For Western Blot analysis, samples 
were homogenized and protein concentrations estimated via bicinchoninic acid assay (Thermo 
Scientific).  Protein (10 µg) in a 1:1 loading buffer (450 µl Laemmli + 50 µl βME) ratio were 
loaded and run on a 4-15% electrophoresis gel (BioRad) at 100 V for 10 min followed by 200 V 
for 25 min.  The separated proteins were then transferred to a nitrocellulose membrane at 100 V 
for 1 hr, blocked with 5% milk in TBS-T (Tris Buffered Saline with 0.05% Tween 20) and then 
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probed with Synapsin-1 antibody (1:1000; Sigma) and GAPDH (1:1000; Santa Cruz) to control 
for loading, overnight at 4°C.  The membrane was then washed and incubated in anti-rabbit 
secondary antibody (1:1000; Cell Signaling Technology) for 2 hrs prior to chemiluminescent 
substrate (BioRad) exposed for 5 min and imaged via a BioRad ChemiDoc Touch Gel Imaging 
System (BioRad).  To account for gel/run differences, each gel was loaded with a homogenate 
sample lane (sample which composed of multiple mouse brains pooled together).  The relative 
intensity of Synapsin-1 was determined by dividing its optical density, determined using Image 
Lab v5.2.1 (BioRad), by GAPDH, and then divided by the homogenate sample lane’s Synapsin-
1/GAPDH Ratio.   
Hyperactivity Assessment 
 
 FXS mice and subjects have been established to exhibit increased hyperactivity compared 
to controls (Bakker et al., 1994; Hagerman and Hagerman, 2003; Kazdoba et al., 2014). To 
assess the effects of each blocker on FXS hyperactivity, the total distance traveled, average 
velocity, and maximum velocity over 10 minutes was assessed using Anymaze (v4.98) during 
Novel Object Recognition Habituation as previously described (Belagodu et al., 2017). 
Open Field Assessment 
 
 FXS patients and mice also exhibit increased anxiety levels (Hagerman and Hagerman, 
2003; Cordeiro et al., 2011; Bailey et al., 2012).  To assess anxiety, a standard Open Field 
assessment exploring the time spent in the center (Center 50%), corners, edges, crossings into 
center area, and the amount of time immobile in the center region of the training cage during 
habituation (10 min) was conducted using Anymaze (v4.98). 




 Marble Bury, a well-established paradigm for repetitive (stereotypy) behavior (Thomas et 
al., 2009), was used to assess the beneficial effects of Receptor Blocker treatments.  To assess 
stereotypic behavior, a modified protocol from (Deacon, 2006) was used.  As previously 
described, mice were placed in a new cage consisting of 5 cm of woodchip bedding and 15 
evenly spaced (at least 1 inch apart) glass marbles for 30 minutes.  The mice were then removed, 
and the number of marbles buried was assessed.  Marbles were considered fully buried if they 
were more than 50% covered.  The Marble Bury Assessment was conducted prior to injections 
with a follow up test after drug treatment to obtain within subject assessments.   
Testicle Weight 
 
 Macroorchidism is a prominent feature in FXS males, driven by excessive Sertoli cell 
proliferation (Slegtenhorst-Eegdeman et al., 1998).   Testicular weight has been previously 
shown to be a viable metric for assessing macroorchidism in adult mice (Kooy et al., 1996; 
Belagodu et al., 2017).  To assess each VEGF Receptor’s influence on testicle weight, FXS 
(n=37) and WT (n=12) mice were dosed with either MF-1 (n=9), DC101 (n=9), mF4-31C1 
(n=10), or Saline (n=21) in the aforementioned dosage scheme.  Immediately following the last 
behavioral assessment, testicles were removed and post-fixed in 4% paraformaldehyde for 24 
hrs.  After post-fixing, testicles were desiccated for 2 days and then weighed.  For statistical 
analyses, each testicle was considered an individual unit. 
Statistical Analyses 
  
 All statistical analyses were conducted with a 2-way mixed model ANOVA on SAS 
(http://www.sas.com/en_us/home.html) with either genotype and/or drug as between subject 









 VEGF-A’s primary targets are VEGFR1 and VEGFR2, suggesting that the effects 
observed while utilizing the VEGF-A blocker Bevacizumab were primarily driven by one of 
these receptors.  Furthermore, VEGFR3 is involved with lymphangiogenesis (Kukk et al., 1996; 
Paavonen et al., 2000; Alitalo and Carmeliet, 2002), is activated by VEGF-C and VEGF-D 
(Joukov et al., 1996; Achen et al., 1998), and could provide new insight into potential 
mechanisms mediating FXS deficits.  Western Blot analyses demonstrated that the higher doses 
(50 mg/kg) of VEGFR2 (DC101) and VEGFR3 (mF4-31C1) receptor blockers significantly 
reduced Synapsin-1 expression.  No significant effects were observed with the lower doses (25 
mg/kg) [Fig. 6.3; F(7,16)=9.70; p<0.005].  Based upon these findings, behavioral assessments 
mirroring those in our prior FXS VEGF-A blocker study were pursued; Hyperactivity and Open 
Field Assessments, Stereotypy Measures of Marble Bury and Rotations, and testicle weight  






Figure 6.3. High doses of DC101 (VEGFR2 Blocker) and mF4-31C1 (VEGFR3 Blocker) 
decreased Synapsin-1 in FXS mouse brain.  Synapsin-1 expression after 10 days of treatment 
with either Saline, MF-1 (VEGFR1 Blocker), DC101 (VEGFR2 Blocker), or mF4-31C1 
(VEGFR3 Blocker).  No significant reduction in Synapsin-1 expression was observed with a low 
dose (25mg/kg); however, the higher dose (50mg/kg) of DC101 and mF4-31C1 significantly 




 Hyperactivity is a well-known FXS abnormality with FXS mice exhibiting increased total 
distance traveled, and velocity (Bakker et al., 1994; Belagodu et al., 2017).  Consistent with 
previous studies, our study demonstrated that FXS saline treated mice displayed increased 
hyperactivity (distance traversed [Fig. 6.4a; F(4,485)=13.03; p<0.005], overall mean velocity [Fig. 
6.4b; F(4,485)=13.02; p<0.005], and overall max velocity [Fig. 6.4c; F(4,485)=8.00; p<0.005]).  
Interestingly, the receptor blockers did not alter overall hyperactivity in the aforementioned 
metrics.  This is in line with our previous study assessed the effects of blocking VEGF-A, in 





Figure 6.4. Measures of hyperactivity comparing WT mice to FXS mice treated with saline or 
one of three VEGF Receptor Blockers.  None of the VEGF receptor blockers significantly 
alleviated any of the hyperactivity measures.  a. Average distance covered per minute in the 
training chamber.  FXS mice had significantly increased movement.  b. Average velocity per 
minute in the training chamber.  FXS mice moved significantly faster than WT mice.  c. Average 
maximum velocity per minute.  FXS mice reached significantly higher speeds than WT mice.  
*<0.05.   
 
Open Field Assessment 
 
 The Open Field Paradigm was utilized to assess general locomotor activity and anxiety-
like behavior.  Previous studies have shown that FXS mice display decreased anxiety and 
increased overall levels of locomotion (Peier et al., 2000; Spencer et al., 2005).  Although the 
initial metrics of locomotion (distance traveled, mean velocity, and max velocity) were already 
assessed in our discussion of hyperactivity this analysis found that FXS mice were also mobile 
for a greater amount of time [Fig. 6.5a; F(4,485)=12.92; p<0.005] with more mobile episodes [Fig. 
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6.5b; F(4,485)=10.95; p<0.005] and displayed less immobility time [Fig. 6.5c; F(4,485)=12.93; 
p<0.005] with a decreased amount of immobile episodes [Fig. 6.5d; F(4,485)=10.77; p<0.005].  
These measures further suggest a reduction in anxiety and increased exploratory behavior.  This 
was further corroborated with FXS mice exhibiting an increased number of crossings [Fig. 6.5e; 
F(4,485)=11.95; p<0.005], particularly to/from the center zone [Fig. 6.5f; F(4,484)=5.86; p<0.005]; a 
behavior consistent with reduced anxiety.  Unfortunately, none of the receptor blockers 
significantly reduced any locomotor (Fig. 6.5a-d) or anxiety-like behavioral measures (Fig. 6.5c-
f), suggesting that the VEGF Receptors are not involved in the pathways that dictate these 
phenotypes.  Interestingly, our analysis of rotations, a measure of stereotypy, found that FXS 
mice, consistent with prior studies (Dolan et al., 2013), exhibit increased rotations (~32%); 
however, blocking VEGFR2 in FXS significantly reduced the number of rotations to control 
levels [Fig. 6.5g; F(4,485)=11.16; p<0.005]. 
 


















Figure 6.5 (cont.). Open Field Assessment metrics for locomotion (a.-d.), anxiety-like (c.-f.), and 
stereotypy behavior (g.) in WT vs FXS mice treated with saline or one of three VEGF Receptor 
Blockers.  Treatment yielded no effect on locomotion or anxiety-like behaviors, but DC101 
(VEGFR2 Blocker) was able to rescue stereotypy behaviors.  a. Percent time in which the mice 
were mobile per minute in the training chamber.  FXS mice were more mobile for significantly 
longer than WT mice.  b. Mobility bouts per minute in the training chamber.  FXS mice had 
significantly fewer number of instances in which they were mobile than WT mice.  c. Percent 
time in which the mice were immobile per minute in the training chamber.  FXS mice were 
immobile for significantly less time than WT mice.  f. Immobility bouts per minute in the 
training chamber.  FXS mice had significantly fewer instances in which they were immobile than 
WT mice.  g. Total crossings per minute in the training chamber.  FXS had significantly more 
crossings than WT mice.  h. Crossings to/from the center region per minute in the training 
chamber.  FXS mice had significantly more crossings in the center region than WT mice.  g. 
Total rotations per minute in the training chamber.  FXS rotated significantly more than WT 
mice and DC101 alleviated this deficit.  *<0.05.   
 
Marble Bury Analysis 
 
 The main metric for stereotypy behavior was assessed via Marble Bury.  Consistent with 
previous FXS rodent studies (Spencer et al., 2011; Veeraragavan et al., 2012; Gholizadeh et al., 
2014), FXS mice displayed increased stereotypy behavior expressed by increased burrowing 
behavior, and a (~46%) increase in the number of marbles buried.  Two FXS (Saline), one FXS 
(VEGFR1) and one WT (Saline) mouse were removed from the analysis as their mean number of 
marbles buried were more than two standard deviations from their group mean. Our analyses 
demonstrated that the receptor blockers (MF-1, DC101, & mF4-31C1) did not alter the number 
of marbles buried [Fig. 6.6; F(6,84)=6.93; p<0.005]. This is further addressed in the discussion 





Figure 6.6. Stereotypy behavior of Marble Burying was not altered with 10 days of treatment 
with any VEGF Receptor Blocker.  FXS mice bury more marbles than their WT counterparts.  
All FXS treatment groups buried significantly more marbles compared to WT Saline control 




 Macroorchidism is a prominent phenotype of FXS subjects (McLennan et al., 2011) and 
FXS mice (Slegtenhorst-Eegdeman et al., 1998; Hagerman and Hagerman, 2003).  Consistent 
with our previous findings (Belagodu et al., 2017), FXS mice displayed enlarged (~37%) testes 
compared to their WT counterparts [Fig. 6.7; F(4,93)=14.65; p<0.005].  Interestingly, neither 
VEGFR1 or VEGFR2 significantly altered teste weight.  However, mF4-31C1 (VEGFR3 
Blocker) significantly decreased in teste weight (~11%)  compared to FXS mice, but was still 





Figure 6.7. Blocking VEGF Receptors do not decrease FXS testicle weight to WT levels.  
However, blocking with mF4-31C1 (VEGFR3 Blocker), significantly decreases teste weight 




 Prior studies have demonstrated that the VEGF Pathway may be a target for mediating 
FXS molecular and behavioral abnormalities (Belagodu et al., 2017).  Specifically, our previous 
studies have demonstrated that blocking VEGF-A via Bevacizumab in FXS can reduce 
Synapsin-1 levels in both the visual cortex and CA1 of the Hippocampus.  A reduction in 
Synapsin-1 levels suggests decreased synapse density, as Synapsin-1 expression has been shown 
to directly correlate with synapse number (Sudhof et al., 1989; Cesca et al., 2010).  This 
reduction is believed to be the primary cause for the beneficial effects of Bevacizumab treatment 
on FXS Novel Object Recognition abnormalities (Belagodu et al., 2017).  The following study 
sought to determine which of the VEGF Receptors were mediating these beneficial effects seen 
with blocking VEGF-A. 
 VEGF Receptors have been suggested to be involved in more than angiogenesis, 
particularly in adulthood.  VEGFR1 has been extensively found on astrocytes, and is believed to 
regulate astroglial expression of various growth factors (Krum et al., 2008; Koyama et al., 2014).  
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However, blocking VEGFR1 with MF-1 did not significantly alter FXS Synapsin-1 levels in the 
brain.  
VEGFR2 has been found on axonal growth cones (Sondell et al., 1999) with stimulation 
via VEGF-A promoting neurite outgrowth (Jin et al., 2006).  Furthermore, it has been implicated 
as a key driver in microvascular permeability (Dvorak, 2002).  Interestingly, VEGFR2 has 
recently been observed to influence learning mechanisms in rodents, as genetic removal of these 
receptors impairs contextual fear conditioning acquisition (De Rossi et al., 2016).  Our findings 
suggest that blocking VEGF Receptors can alter synapse density; however, it has varying results 
on behavioral.  Whole brain Synapsin-1 levels were significantly reduced with 50mg/kg of 
DC101.  This is further corroborated with our previous study in which blocking VEGF-A, the 
primary ligand for VEGFR2 (Dvorak, 2002), resulted in a similar decrease in Synapsin-1 levels 
(Belagodu et al., 2017).   
Finally, blocking VEGFR3 with 50 mg/kg of mF4-31C1 also significantly reduced FXS 
brain Synapsin-I expression. VEGFR3 is the main lymphangiogenic receptor, mediating the 
generation and proliferation of lymphatic vessels (Kukk et al., 1996; Paavonen et al., 2000; 
Alitalo and Carmeliet, 2002).  Lymphatic vessels are lined with endothelium, which mediates the 
blood brain barrier and permeability (Feletou, 2011).  Interestingly, VEGFR3 and the lymphatic 
vessels have recently been discovered to have a neuronal role in the Central Nervous System 
(CNS); lymphatic vessels have been discovered in the dural sinuses, and function to help 
mitigate fluid and immune cells to and from the Cerebral Spinal Fluid (CSF) and CNS (Louveau 
et al., 2015), thus suggesting their influence on mediating blood brain barrier permeability.    
Furthermore, application of VEGF-C and subsequent activation of VEGFR3 have been shown to 
increase hippocampal neurogenesis (Han et al., 2015).  This increased neuronal function, 
115 
 
particularly the influence in hippocampal neurogenesis mirrors that of VEGFR2’s ability to 
increase hippocampal neurogenesis (Jin et al., 2002), and thus could indicate a new potential 
mechanism for mediating FXS abnormalities. 
Our behavioral findings of increased anxiety, hyperactivity, and stereotypy in FXS mice 
are consistent with those from other laboratories.  FXS mice displayed phenotypic characteristics 
of reduced anxiety such as increased mobility and crossings to/from the center region (Peier et 
al., 2000; Spencer et al., 2005); however, blocking the VEGF receptors did not alter anxiety 
levels in FXS mice.  Stereotypy behavior was primarily assessed through Marble Bury in which 
FXS mice exhibited increased number of marbles buried (Spencer et al., 2011; Veeraragavan et 
al., 2012; Gholizadeh et al., 2014); however, blocking the VEGF receptors did not alleviate this 
abnormality.  Interestingly, another measure of stereotypy behavior, rotations per minute in 
which FXS mice tend to rotate more than WT mice during exploration, was alleviated with 
DC101 the VEGFR2 blocker.  When combined with the Marble Bury assessment, these findings 
suggest a partial rescue of overall stereotypy behavior.  Further analyses will be necessary to 
determine the biological pathways mediating these different aspects of stereotypy behavior, and 
how the VEGF pathway could be mediating them. 
This inability to rescue stereotypy behavior could be attributed to an inability of these 
interventions in alleviating hyperactivity.  Stereotypy behaviors are heavily influenced by the 
mouse’s general locomotion levels, and thus could mask any potential benefits the VEGFR 
blockers are having.  Further analysis into new behavioral paradigms and their connection with 
the VEGF pathway would be required to fully assess the effects of blocking VEGFR2 and the 
other receptors on measures of anxiety and stereotypy.   
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Our previous study demonstrated that the effects of blocking VEGF-A were global, as 
Bevacizumab treatment also reduced FXS teste weight (Belagodu et al., 2017).  FXS mice 
displayed phenotypic macroorchidism (Slegtenhorst-Eegdeman et al., 1998; Hagerman and 
Hagerman, 2003); however, treatment with the receptor blockers were unable to reduce testicle 
weight to WT levels.  Interestingly, mF4-31C1, the VEGFR3 blocker, did have a significant 
decrease in teste weight, but were still significantly heavier than WT mice. 
The benefits of blocking VEGF receptors on FXS abnormalities require further 
investigation. While initial molecular effects, observed with the reduction in Synapsin-1 levels 
were promising, the subsequent behavioral analyses were unable to adequately delineate a 
beneficial effect for any of the VEGFR blockers. Understanding the full extent of the molecular 
influences can help to better ascertain the ability of the receptor blocks in mediating FXS 
cognitive and behavioral abnormalities.  Furthermore, utilizing the observed 
anatomical/molecular changes can be used to determine an ideal dosing scheme for subsequent 
analyses.  This study provides the ground work for a potential mechanism mediating some FXS 
abnormalities, and thus potentially providing new therapeutic targets for treating these 




CHAPTER 7: GENERAL DISCUSSION 
 
 The studies in this Dissertation sought to examine the role of Vascular Endothelial 
Growth Factor (VEGF) and its effects on abnormalities in the mouse model of Fragile X 
Syndrome (FXS); a novel mechanism mediating FXS abnormalities.  Our findings demonstrated 
a developmental dysregulation of brain blood vessel density (BVD).  Specifically, we found that 
in WT mice, there was increased vasculature at PND 20 with a sharp reduction at PND 35; 
however, in FXS mice there was a gradual increase in BVD through development and into 
adulthood.  These findings are consistent with our prior analyses demonstrating increased BVD 
in adult and aged FXS mice (Galvan and Galvez, 2012) and studies demonstrating abnormal 
blood perfusion in FXS patients (Balci et al., 2006).  This BVD deficit in FXS mice could result 
in a developmental delay in vascular brain growth and proliferation at PND 20, that is 
overcorrected through adulthood with increased BVD at PND 60 (adulthood).  Consistent with 
these findings we further demonstrated developmental dysregulation of the VEGF family of 
molecules and their respective receptors.  However, further analyses will be needed to determine 
the specific implications of the altered protein expression on FXS neuronal properties and 
behavior.  To ascertain a potential mechanism for this alteration in VEGF levels, rapamycin was 
utilized to inhibit mTORC1.  Application of rapamycin resulted in decreased expression of 
VEGF-A in FXS.  These findings suggest that VEGF-A production is downstream of mTORC1 
and potentially involved in the mGluR pathway (Belagodu et al., 2017).  The mGluR pathway is 
the prevailing theory for the abnormalities in FXS (Bear et al., 2004), and thus could provide a 
potential novel target for treating FXS abnormalities. 
 Our subsequent analyses found that blocking VEGF-A with Bevacizumab reduced FXS 
elevated Synapsin-1 levels in whole brain and specifically in the visual cortex and CA1 of the 
118 
 
hippocampus (Belagodu et al., 2017).  Synapsin-1 is a pre-synaptic vesicle binding protein 
whose expression correlates with synapse number (Sudhof et al., 1989; Cesca et al., 2010).  
Interestingly, a follow up study utilizing VEGF receptor specific blockers demonstrated that 
blocking VEGFR2 or VEGFR3 resulted in a similar reduction in Synapsin-1 whole brain protein 
expression, suggesting that the effects of blocking VEGF-A on Synapsin-I expression are 
working through one of these receptors. 
 To assess if blocking VEGF-A mediated activity has any beneficial behavioral effects, 
FXS mice were initially tested on the Novel Object Recognition paradigm.  Mice are 
ethologically exploratory in nature, and readily examine novel objects.  However, FXS mice do 
not exhibit this preference as they are unable to recall which object had been previously explored 
(Ventura et al., 2004; Seese et al., 2014; Bhattacharya et al., 2016).  Our findings demonstrated 
that treatment with Bevacizumab was able to alleviate this deficit, as Bevacizumab treated FXS 
mice had preferential exploration for the novel object during testing (Belagodu et al., 2017).  To 
assess the extent that Bevacizumab and the Receptor Blockers can alleviate FXS abnormalities, 
we subsequently explored their effect on paradigms FXS mice are known to be deficit in: 
hyperactivity (Bakker et al., 1994; Hagerman and Hagerman, 2003; Kazdoba et al., 2014), 
anxiety (Hagerman and Hagerman, 2003; Cordeiro et al., 2011), and stereotypy (repetitive) 
behavior (Thomas et al., 2009; Spencer et al., 2011; Veeraragavan et al., 2012; Gholizadeh et al., 
2014).  In addition to these behavioral measures, there has been a push to establish more 
clinically relatable metrics to validate animal studies (Berry-Kravis et al., 2008; Berry-Kravis et 
al., 2013; Jacquemont et al., 2014).  Thus, to address this concern, vocalization properties in FXS 
mice were also assessed.     
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 FXS patients suffer communication deficits, manifesting in increased articulation errors, 
Palilalia, disfluency, and reduced quality of sentence structure (Van Borsel et al., 2008).  
Furthermore, many of the clinical measures, particularly those with higher reproducibility rely on 
communication and verbal responses (Berry-Kravis et al., 2008), furthering the need to find an 
analogous rodent model.  Through testing adult mice in a courtship/separation paradigm, we 
found that FXS mice exhibit altered vocalization production.  Specifically, FXS mice produced 
vocalizations with more frequency jumps (syllables) and more syllables in each call (phrases).  
These phrases contained more repeated units (motifs) compared to their WT counterparts.  
Furthermore, FXS mice produced fewer isolated syllables, suggesting an inability for proper 
vocalization formation (Belagodu et al., 2016).  These findings suggest that assessing 
vocalization patterns could be a potential novel venue for assessing the efficacy of treatments in 
FXS mice, and thus was further explored following VEGF-A modulation in the subsequent 
studies. 
Collectively, the aforementioned experiments suggest that modulating VEGF-A and the 
VEGF pathway could be a potential treatment mechanism for FXS deficits.  Our previous studies 
demonstrated that treatment with Bevacizumab, VEGFR2, or VEGFR3 Blockers can reduce 
overall Synapsin-1 levels in FXS mice; however, neither of these or the VEGFR1 Blocker 
modulated hyperactivity (Belagodu et al., 2017), anxiety, marble burying, or vocalization 
deficits.  Interesting, our analysis of the number of rotations per minute in FXS found that it was 
reduced by blocking VEGFR2 but not with Bevacizumab or any of the other receptor blockers.  
This suggests that there may be some influence of this pathway on these behaviors, but as 
previously mentioned, might not be the major contributing factor as other metrics were not 
altered.   
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Although blocking VEGF-A activity did not alleviate locomotor activity, anxiety-like 
behavior, stereotypy behaviors, or vocalization deficits, our previous studies demonstrated that it 
was able to rescue more cognitive paradigms such as Novel Object Recognition (Belagodu et al., 
2017).  This could suggest a potential limitation in modulating VEGF-A in FXS mice, as its 
benefits could be confined to more cognitive tasks.  To ascertain this specificity, further 
investigation into not only which paradigms can be rescued, but region specific expression levels 
of Synapsin-1 would be beneficial.  A focus on more cognitively demanding paradigms such as 
Morris Water Maze or Trace Fear Memory Tasks which FXS mice are known to be deficit in 
(Shang et al., 2009) could aid in understanding the full effects and potential benefits of VEGF-A 
modulation in adult FXS mice.   
In moving forward with the findings from this dissertation, several lines of research 
should be pursued.  An extensive region specific examination of alterations in Synapsin-1 levels 
via Western Blot and Immunohistochemistry (IHC) could offer important insight on the extent of 
Bevacizumab’s influence in the brain and thus lead to a better understanding of which FXS 
behavioral phenotypes would benefit from such an intervention.  Furthermore, understanding 
what changes are occurring on a cellular level to the neurons in these regions would be extremely 
beneficial.  A reduction in Synapsin-1 was observed, but it is currently unknown if this translates 
to alterations in dendritic spine properties.  A follow up anatomical study utilizing Golgi staining 
to ascertain neuron dendritic spine morphology can provide additional insight into which of these 
interventions can influence FXS mouse neuronal abnormalities.  These studies could also help 
suggest if the treatment should be extended to obtain a greater effect on spine morphology, and 
potentially alleviate behavioral abnormalities.  Utilizing these analyses to determine an ideal 
dosage, time point for intervention, and length of intervention could help further elucidate the 
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behavioral benefits of these interventions.  Furthermore, this would be highly beneficial for 
translational research, as dosage, length, and adequate behavioral metrics are all growing 
concerns with FXS translational research (Jacquemont et al., 2014).    
In addition to the neuronal effects, our analyses demonstrated that the effects of these 
interventions are global, as Bevacizumab treatment also reduced FXS overall teste weight to WT 
levels.  Much to our surprise treatment with the receptor blockers only partially reduced teste 
weight.  Further analyses will be needed to elucidate the underlying mechanisms mediating this 
effect and how blocking VEGF-A can alleviate it. 
Collectively, the studies covered in this dissertation suggest that modulating VEGF-A 
and its receptors, particularly VEGFR2 and VEGFR3 can alter FXS behavioral, cellular and 
molecular properties.  However, the observed rescue in FXS behavioral deficits are not universal, 
but rather specific towards particular abnormalities.  Specifically, abnormalities in hyperactivity 
appear to be unaffected.  These studies suggest that modulation the VEGF family of molecules 
and their receptors could be a novel mechanism for treating certain FXS abnormalities and that a 
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